LIBERTY
Academic Books



EDITOR
Dr. Jasmine M. Hooks

VACCINE POLICIES: LEGAL, ETHICAL AND SCIENTIFIC FOUNDATIONS

Liberty Publishing House
New York - 2025

VACCINE POLICIES: LEGAL, ETHICAL AND SCIENTIFIC FOUNDATIONS- 2025

ISBN: 979-8-89695-138-4

DOI: 10.5281/zenodo.16793052

Edited By

Dr. Jasmine M. HOOK

August / 2025

New York / USA



Date: 11.08.2025

Liberty Publishing House
Water Street Corridor New York, NY 10038
www.libertyacademicbooks.com
+1 (314) 597-0372

adopted by Mariam Rasulan&Merve Küçük
ISBN: 979-8-89695-138-4

VACCINE POLICIES: LEGAL, ETHICAL AND SCIENTIFIC FOUNDATIONS

EDITOR
Dr. Jasmine M. HOOKS

AUTHORS
Prof. Dr. R.SRINIVASAN
Assoc. Prof. Dr. Demet ÇELEBI
Tavneet KAUR
Bello Hassan ONIMISI
R.VIDHYALAKSHMI
G. PRATHEEBA
C. REJITHA
Arshan SHAFQAT
Zohaib SAEED
Saifullah RASHID

TABLE OF CONTENTS

PREFACE

Vaccination stands among the most transformative achievements in the history of public health, safeguarding countless lives and reshaping the trajectory of infectious diseases. This volume, Vaccine Policies: Legal, Ethical and Scientific Foundations, brings together diverse scholarly perspectives on the legal frameworks, ethical considerations, scientific advancements, and public health strategies that underpin vaccine development and deployment. By examining both historical milestones and contemporary challenges—from intellectual property debates to equitable access—these chapters offer critical insights for policymakers, healthcare professionals, and researchers alike.

We extend our sincere gratitude to all chapter authors for their valuable contributions, rigorous scholarship, and dedication to advancing knowledge in this vital field. Their expertise and commitment have been essential in shaping this work into a comprehensive and impactful resource.

Dr. Jasmine M. Hooks
Editor
New York, 2025

CHAPTER 1

LEGAL AND ETHICAL DIMENSIONS OF VACCINE DEVELOPMENT

[1] Tavneet KAUR

[1]Punjab University, Academic Research Scholar, Chandigarh, 0009-0005-4131-9573

INTRODUCTION

Vaccines have played a crucial role in public health by preventing the spread of infectious diseases and reducing morbidity and mortality worldwide. Since the discovery of the smallpox vaccine by Edward Jenner in 1796, vaccines have continuously evolved, protecting humanity from deadly outbreaks such as polio, measles, and, most recently, COVID-19. The importance of vaccines lies not only in their ability to prevent individual infections but also in their contribution to herd immunity, which safeguards entire populations, including those who cannot be vaccinated due to medical conditions. With scientific advancements, modern vaccines have become more effective, but their development and distribution remain complex processes influenced by legal, ethical, and medical considerations. These factors shape how vaccines are researched, tested, approved, and made accessible to the public. Despite their undeniable benefits, vaccines have frequently been at the center of legal and ethical debates. Governments worldwide impose stringent regulations to ensure the safety and efficacy of vaccines before they are made available to the general public. These regulatory frameworks, established through international and national laws, are essential to prevent unethical experimentation and ensure that vaccines undergo rigorous clinical trials. However, striking a balance between rapid vaccine development and adherence to legal protocols is a persistent challenge, especially in the context of public health emergencies like the COVID-19 pandemic. The urgency to curb outbreaks often necessitates expedited vaccine approval processes, leading to concerns over whether regulatory safeguards might be compromised in favour of speed. This tension between scientific progress and legal accountability highlights the critical role of regulatory bodies such as the World Health Organization (WHO), the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO) in overseeing vaccine development and approvals.

Ethical considerations are equally significant in vaccine research and deployment. Informed consent, an essential principle in medical ethics, requires that individuals participating in clinical trials fully understand the potential risks and benefits of the vaccine being tested. However, history has shown instances where vulnerable populations were subjected to unethical medical

trials without proper consent. One of the most controversial cases was the Pfizer drug trial in Nigeria in 1996, where children were administered an experimental antibiotic without adequate information provided to their families. Similarly, the development of the COVID-19 vaccine raised concerns about whether trial participants, particularly in low-income countries, had been given sufficient details about potential adverse effects. Ethical lapses in vaccine research undermine public trust and can lead to vaccine hesitancy, making it imperative to enforce strict ethical guidelines in clinical trials. The debate over mandatory vaccination policies further exemplifies the intersection of law and ethics in vaccine development. Governments, in their responsibility to protect public health, often implement vaccine mandates, requiring individuals to receive certain vaccines to access schools, workplaces, or public services. While such mandates have successfully controlled diseases like measles and polio, they also raise fundamental questions about individual autonomy and bodily integrity. The landmark 1905 case of Jacobson v. Massachusetts in the United States set a precedent by ruling that states could enforce compulsory vaccination laws in the interest of public health. However, the issue remains contentious, as seen during the COVID-19 pandemic, where several countries faced legal challenges against vaccine mandates imposed on healthcare workers and the general population. The Indian Supreme Court, for instance, held that while vaccination is essential for public health, it should not infringe upon an individual's right to personal liberty unless there is a significant threat to others. This delicate balance between public welfare and personal freedom makes legal frameworks crucial in determining how vaccine mandates are implemented and challenged in courts. Another critical legal issue in vaccine development is intellectual property rights, which determine the accessibility and affordability of vaccines. The COVID-19 pandemic brought global attention to the impact of patent laws on vaccine equity. Pharmaceutical companies that invested in vaccine research and development sought patent protections under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), allowing them to control vaccine production and pricing. However, this led to widespread disparities in vaccine access, with wealthier nations securing large supplies while developing countries struggled to obtain sufficient doses. In response, India and South Africa proposed a temporary waiver on COVID-19

vaccine patents to the World Trade Organization (WTO), arguing that intellectual property protections should not obstruct global health initiatives. The debate highlighted the ethical dilemma of balancing commercial interests with the moral obligation to ensure equitable vaccine distribution, especially during a global crisis. Compulsory licensing, which allows governments to permit local manufacturers to produce patented vaccines without the patent holder's consent, emerged as a potential solution to address these inequities. However, such measures often face legal and diplomatic resistance from major pharmaceutical companies and developed nations.

Beyond the legalities of vaccine patents and mandates, misinformation surrounding vaccines has also become a pressing concern with ethical and legal implications. The rapid spread of misinformation through social media platforms has fuelled vaccine hesitancy, leading to decreased vaccination rates and the resurgence of preventable diseases. False claims about vaccine safety, such as the widely discredited study linking the MMR (measles, mumps, and rubella) vaccine to autism, have persisted despite scientific evidence proving otherwise. The ethical responsibility of governments, healthcare institutions, and media organizations is to provide accurate and transparent information to counteract vaccine misinformation. In some countries, legal actions have been taken against individuals and organizations that spread false vaccine-related claims, demonstrating that misinformation is not just a public health issue but also a legal matter. Considering these complexities, the purpose of this chapter is to provide an in-depth analysis of the legal and ethical dimensions of vaccine development, with a focus on real-world case studies that illustrate the challenges and implications of regulatory frameworks, ethical considerations, and legal disputes. The discussion will examine international and national laws governing vaccine research, ethical dilemmas in clinical trials, vaccine mandates, intellectual property rights, and the legal consequences of misinformation. By exploring these aspects, the chapter aims to contribute to a broader understanding of how law and ethics influence vaccine policies, ensuring that public health initiatives remain both effective and just. Looking ahead, vaccine development is not merely a scientific endeavour; it is deeply intertwined with legal and ethical concerns that shape how vaccines are researched, distributed, and administered. While legal frameworks provide the

necessary structure to regulate vaccine development and protect public health, ethical considerations ensure that medical advancements uphold fundamental human rights. Striking the right balance between these aspects is crucial for fostering public trust in vaccines and ensuring that life-saving immunization programs are accessible and equitable. As the world continues to face emerging infectious diseases and public health crises, the role of law and ethics in vaccine development will remain critical in addressing the challenges of the future.

1. LEGAL FRAMEWORK GOVERNING VACCINE DEVELOPMENT

The legal framework governing vaccine development consists of international and national regulations that ensure the safety, efficacy, and equitable distribution of vaccines. Organizations like the WHO, FDA (USA), EMA (Europe), and CDSCO (India) play crucial roles in regulating vaccine trials, approvals, and distribution. Intellectual property laws, such as the TRIPS Agreement**,** influence vaccine accessibility, while national policies determine mandates and liability protections. Legal challenges often arise regarding vaccine mandates, patent restrictions, and ethical concerns in clinical trials. A well-structured legal system is essential to balance public health priorities with individual rights and corporate interests in vaccine development.

1.1 International Regulations and Guidelines

Vaccine development is a highly regulated process, requiring compliance with strict international and national legal frameworks to ensure safety, efficacy, and equitable access. Since vaccines impact public health on a global scale, international organizations such as the World Health Organization (WHO), the World Trade Organization (WTO), and regulatory agencies in various countries play an essential role in shaping vaccine policies and approval processes. These legal frameworks ensure that vaccines undergo rigorous clinical trials before mass distribution while also addressing concerns related to intellectual property rights, equitable access, and public safety. The World Health Organization (WHO) has established extensive guidelines on vaccine research, development, and distribution. WHO's "Guidelines on Clinical Evaluation of Vaccines" emphasize the importance of ethical trials, robust testing protocols, and

transparency in reporting vaccine efficacy and side effects. WHO also supervises global immunization programs through initiatives such as COVAX, which aims to provide vaccines to low-income countries. However, the effectiveness of these guidelines depends on how well individual nations incorporate them into their domestic legal frameworks. One of the most debated legal aspects of vaccine development is intellectual property rights (IPR), particularly in the context of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement under the WTO. TRIPS provides patent protection to pharmaceutical companies, allowing them to control the production and distribution of newly developed vaccines. While patent laws encourage innovation, they also create challenges in ensuring equitable access to vaccines, especially during global health emergencies. The COVID-19 pandemic highlighted this issue when developing countries struggled to acquire vaccines due to high costs imposed by patent-holding pharmaceutical companies. In response, India and South Africa led a proposal at the WTO to waive TRIPS patent protections for COVID-19 vaccines, arguing that public health emergencies should take precedence over corporate profits. Although the proposal gained significant support, it faced resistance from developed nations, demonstrating the complexity of balancing legal rights with humanitarian concerns.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO) oversee vaccine approval processes in their respective regions. The FDA follows a rigorous Biologics License Application (BLA) process, requiring extensive clinical trial data before approving vaccines for public use. Similarly, the EMA evaluates vaccines under the Centralized Procedure, ensuring that approved vaccines meet high safety and efficacy standards across the European Union. In India, the CDSCO operates under the Drugs and Cosmetics Act, 1940, which was updated to incorporate stringent guidelines for vaccine approval, especially after the COVID-19 crisis. The accelerated approval of vaccines like Covaxin, India's indigenous COVID-19 vaccine, raised concerns regarding the speed of regulatory approvals and the balance between emergency responses and thorough clinical trials. A case study that highlights the complexity of vaccine

approval is the approval process of Covaxin in India. Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), received Emergency Use Authorization (EUA) in January 2021. The approval was initially controversial due to the absence of Phase III clinical trial data at the time of authorization. Critics argued that the expedited approval process compromised regulatory standards, while government officials defended it as a necessary step to combat the pandemic. Subsequent studies confirmed Covaxin's efficacy, but the incident raised legal and ethical concerns regarding emergency vaccine approvals and transparency in regulatory decisions.

1.2 National Laws and Policies on Vaccination

Each country has its own legal framework governing vaccine development, approval, and distribution, shaped by historical experiences with infectious diseases and the need to protect public health. In India, the Drugs and Cosmetics Act, 1940, along with the New Drugs and Clinical Trial Rules, 2019, provides a comprehensive regulatory structure for vaccines. These laws mandate that vaccines undergo preclinical and clinical trials under the supervision of the Central Drugs Standard Control Organization (CDSCO) before they can be approved for public use. The Clinical Trial Rules, 2019, were introduced to strengthen ethical standards in medical research, ensuring that participants in vaccine trials provide informed consent and are protected from exploitation. However, challenges remain in ensuring uniform enforcement of these rules, particularly in rural and underprivileged regions where awareness about clinical trial rights is limited. In the United States, vaccine policies are regulated under laws such as the National Childhood Vaccine Injury Act (NCVIA), 1986, which was enacted to address concerns over vaccine-related injuries and ensure a stable supply of vaccines. The NCVIA established the Vaccine Injury Compensation Program (VICP), which provides financial compensation to individuals who suffer adverse effects from vaccines. This legal framework balances public health interests with individual rights, acknowledging that while vaccines are essential for disease prevention, rare side effects can occur. The existence of such compensation mechanisms enhances public trust in vaccination programs and serves as a model for other

countries seeking to balance liability concerns with the promotion of immunization.

The European Medicines Agency (EMA) oversees vaccine regulation in the European Union, enforcing stringent requirements for vaccine trials and approval. The EU's General Data Protection Regulation (GDPR) also plays a role in vaccine research by ensuring that participants' medical data is protected during clinical trials. In recent years, legal challenges related to vaccine mandates have gained prominence in the EU, particularly in countries where anti-vaccine movements have influenced public opinion. One of the most contentious legal debates regarding vaccines revolves around mandatory vaccination policies. Governments impose vaccine mandates to prevent disease outbreaks, but such policies often face legal challenges on the grounds of personal liberty and bodily autonomy. In the United States, the Supreme Court case Jacobson v. Massachusetts (1905) upheld the government's authority to enforce mandatory vaccination, setting a precedent for future public health laws. However, opposition to vaccine mandates resurfaced during the COVID-19 pandemic, with lawsuits challenging the legality of vaccine requirements for employees and students. In India, vaccine mandates were also contested in courts, with the Supreme Court ruling that while vaccination is essential for public health, it cannot be forcibly imposed on individuals unless there is a compelling state interest. These legal battles underscore the ongoing tension between individual rights and collective health responsibilities.

1.3 Intellectual Property Rights and Patent Issues in Vaccines

A major legal challenge in vaccine development is the conflict between patent protection and public health needs. Pharmaceutical companies invest billions of dollars in vaccine research, justifying their demand for patent protection under the TRIPS Agreement. However, in times of health crises, patent restrictions can hinder access to life-saving vaccines, disproportionately affecting low-income nations. The COVID-19 pandemic exposed the limitations of the existing patent system, as developing countries struggled to procure vaccines while wealthier nations secured large stockpiles through advance purchase agreements. To address these inequities, compulsory licensing has been proposed as a legal mechanism to allow governments to

authorize the production of patented vaccines without the patent holder's consent. India has previously utilized compulsory licensing in the pharmaceutical sector, particularly for affordable HIV/AIDS medication. However, implementing this approach for vaccines remains a complex issue due to international trade regulations and political pressures from patent-holding companies. A notable case study is India's use of compulsory licensing in the pharmaceutical sector, particularly in 2012 when the Indian government granted a compulsory license to Natco Pharma to produce a generic version of Bayer's cancer drug, Nexavar. This decision was based on the argument that the original drug was unaffordable for most patients. While this precedent has not yet been applied to vaccines, it highlights the potential for using legal tools to prioritize public health over corporate interests.

Table 1: Comparison of Vaccine Regulatory Frameworks in Different Regions

Country/Region	Regulatory Body	Key Legislation	Vaccine Approval Process	Legal Challenges
USA	FDA	NCVIA (1986)	Biologics License Application (BLA)	Vaccine injury claims, mandate challenges
EU	EMA	EU Medicines Law	Centralized approval process	GDPR compliance, anti-vaccine movements
India	CDSCO	Drugs & Cosmetics Act (1940)	Clinical trial approvals under 2019 rules	Equity in vaccine access, compulsory licensing

This legal framework highlights the complexities of vaccine development and distribution, demonstrating how different regions address public health needs while navigating legal and ethical challenges. As vaccine technology continues to evolve, so too must the legal systems that regulate it, ensuring that vaccines remain safe, effective, and accessible to all.

2. ETHICAL CHALLENGES IN VACCINE DEVELOPMENT

Vaccine development is not just a scientific and legal process but also an ethical endeavour that involves protecting human rights, ensuring fair access, and maintaining transparency in research. While vaccines have saved millions of lives, their development and distribution raise significant ethical dilemmas, including concerns about informed consent, vaccine access inequalities, government mandates, and misinformation. These challenges often intersect with legal frameworks, requiring a delicate balance between public health priorities and individual freedoms. This section explores the key ethical issues surrounding vaccine development, supported by real-world case studies that illustrate these dilemmas.

2.1 Informed Consent and Clinical Trials

Informed consent is a fundamental ethical principle in medical research, ensuring that individuals participating in clinical trials do so voluntarily and with full knowledge of potential risks and benefits. Vaccine trials, like all medical experiments, require transparency in their objectives, potential side effects, and long-term implications. However, throughout history, there have been cases where vulnerable populations were exploited in vaccine trials without proper informed consent, raising serious ethical concerns.

2.1.1 Case Study: Pfizer's Controversial Drug Trial in Nigeria (1996)

One of the most infamous ethical controversies in clinical trials is Pfizer's 1996 drug trial in Nigeria, which involved testing the antibiotic Trovan on children during a meningitis outbreak. Without proper consent from parents, Pfizer administered the drug to nearly 200 children, leading to severe side effects, including organ failure and death. The trial was later challenged in Nigerian courts, where Pfizer faced allegations of violating medical ethics and exploiting a vulnerable population. The controversy highlighted the ethical need for transparency and informed consent in vaccine and drug trials. It also led to stricter international guidelines, reinforcing that pharmaceutical companies must adhere to ethical protocols, especially when conducting trials

in developing nations. The case serves as a reminder that medical advancements must not come at the cost of human rights violations.

2.1.2 Case Study: Ethical Concerns in AstraZeneca COVID-19 Vaccine Trials in India

During the COVID-19 pandemic, AstraZeneca, in collaboration with the Serum Institute of India (SII), conducted vaccine trials that faced ethical scrutiny. Participants alleged that they were not fully informed of the risks, with some suffering serious neurological side effects. One participant even filed a lawsuit against SII, claiming that the company failed to disclose potential risks. This case reignited debates on the ethical responsibilities of vaccine manufacturers, particularly when conducting trials in countries where regulatory oversight might be weaker. It also emphasized the need for strict ethical review boards to ensure that vaccine trials uphold the highest standards of voluntary participation and transparency.

2.2 Equity and Fair Access to Vaccines

The ethical challenge of vaccine equity has been a long-standing issue, especially in the context of global pandemics. While vaccines are developed as a public good, their availability and affordability remain unequal, disproportionately affecting developing nations. High-income countries often secure vaccine supplies in advance, leaving low-income nations struggling to access life-saving doses. This phenomenon was evident during the COVID-19 crisis, where wealthier countries bought vaccines in large quantities, while developing nations faced severe shortages. Pharmaceutical companies hold patents on vaccines, allowing them to set high prices that many developing nations cannot afford. While initiatives like the COVAX program aimed to ensure global vaccine equity, the actual distribution remained skewed in favour of wealthier nations. The lack of local vaccine production facilities in Africa, South Asia, and Latin America further deepened the crisis. Pharmaceutical firms also face ethical scrutiny for prioritizing profit over public health, often refusing to waive patents or provide technology transfers to boost local vaccine production in developing nations. Such practices raise moral questions about the responsibilities of the private sector in public health emergencies.

Table 2: Vaccine Access Disparities Across Countries (Low vs. High-Income Nations)

Factor	High-Income Nations	Low-Income Nations
Vaccine Availability	High (Stockpiled)	Limited (Shortages)
Price	Affordable due to government subsidies	Expensive relative to national income
Local Production	Advanced facilities	Limited or nonexistent
Vaccination Rates	Over 80%	Below 30%

2.3 Vaccine Mandates vs. Personal Liberty

One of the most controversial ethical debates in vaccine development is the conflict between public health mandates and individual freedoms. While vaccines are crucial for preventing disease outbreaks, some people resist mandatory immunization, arguing that it violates their right to personal liberty and bodily autonomy. Governments worldwide impose vaccine mandates for school enrolment, employment, and travel, leading to legal and ethical challenges. While public health laws prioritize collective welfare, they also raise concerns about coercion and individual rights.

2.3.1 Case Study: India's Supreme Court Stand on COVID-19 Vaccine Mandates

In 2022, India's Supreme Court ruled that COVID-19 vaccination should not be mandatory, emphasizing that personal autonomy must be respected. The court recognized the importance of vaccination but held that no one should be forced to take it against their will unless there was a compelling state interest. This ruling highlighted the ethical balance between individual freedoms and public health safety, reinforcing that vaccine mandates should be implemented with caution and public trust-building rather than coercion.

2.4 Misinformation and Ethical Responsibility of Governments & Media

Misinformation has played a damaging role in vaccine hesitancy, undermining public trust in immunization programs. False claims, particularly through social media, have spread conspiracy theories, discouraged vaccination and led to disease outbreaks. Governments and media have a moral duty to provide accurate information, yet they sometimes fail to counter misinformation effectively. The spread of false information linking vaccines to infertility, autism, or other health risks has fuelled vaccine hesitancy. This hesitancy has led to low vaccination rates, outbreaks of preventable diseases, and unnecessary deaths. Governments have struggled to combat fake news, with some countries even enacting laws to penalize misinformation.

2.4.1 Case Study: The Anti-Vaccine Movement & Its Legal Consequences in the USA

The anti-vaccine movement in the USA gained traction after a 1998 fraudulent study falsely linked the MMR vaccine to autism. This misinformation led to declining vaccination rates and measles outbreaks. The U.S. government responded by implementing strict fact-checking measures and public awareness campaigns to counteract the damage caused by misinformation. This case underscores the ethical duty of governments, pharmaceutical companies, and media platforms to ensure that the public receives scientifically accurate vaccine information.

3. RECOMMENDATIONS AND THE CONCLUDING WAY FORWARD

To ensure ethical and legally sound vaccine development, governments and international organizations must strengthen global regulatory frameworks by harmonizing approval and clinical trial guidelines. Vaccine equity should be prioritized by reforming intellectual property laws, such as revising the TRIPS Agreement to allow compulsory licensing during public health emergencies. Transparency in clinical trials and vaccine distribution must be improved to combat misinformation and restore public trust. Additionally, legal frameworks should balance individual rights with public health needs, ensuring that vaccine

mandates are proportionate and justified in democratic societies. Finally, international cooperation must be reinforced to prevent vaccine nationalism and promote equitable access for all nations.

3.1 Strengthening Global Legal and Ethical Frameworks for Vaccine Development

To ensure that vaccines are developed, tested, and distributed ethically, global legal frameworks must be strengthened and harmonized. While organizations like the WHO, WTO, and national regulatory bodies establish guidelines, there remain gaps in enforcement and uniformity. International treaties should be revised to ensure fair distribution, ethical clinical trials, and transparent approval processes. A globally accepted binding legal framework should be created to prevent unethical testing in vulnerable populations and ensure that pharmaceutical companies follow standardized ethical procedures across all nations.

3.2 Addressing Vaccine Equity Through Legal and Policy Reforms

Vaccine distribution must be more equitable, particularly during pandemics. The TRIPS Agreement should be revised to allow compulsory licensing for vaccines during global health crises. Wealthy nations must be legally bound to contribute a fixed percentage of vaccine stocks to low-income countries. Additionally, increasing local vaccine production capabilities in developing nations through technology transfers and funding initiatives can help reduce reliance on external sources. The failure of COVAX highlights the need for legally enforceable mechanisms to ensure fair vaccine distribution rather than relying on voluntary pledges.

3.3 Enhancing Public Trust Through Transparency and Misinformation Control

Vaccine hesitancy is fuelled by misinformation, lack of transparency in clinical trials, and inconsistent government communication. Governments and international organizations must implement strict fact-checking measures and legal consequences for spreading vaccine misinformation. At the same time,

pharmaceutical companies should publicly disclose all clinical trial data to build trust in the safety and efficacy of vaccines. Public awareness campaigns, combined with regulatory oversight on media platforms, can ensure that scientific facts prevail over conspiracy theories.

CONLUSION

Vaccine development has evolved significantly over the past century, yet it continues to raise complex legal and ethical challenges. While vaccines have played a pivotal role in controlling infectious diseases, ensuring that their research, approval, and distribution processes remain just, transparent, and equitable is critical. The legal framework surrounding vaccine development must strike a balance between incentivizing pharmaceutical innovation and protecting public health interests. While intellectual property rights encourage research and investment, they must not become a barrier to universal vaccine access, particularly during global health crises. The COVID-19 pandemic has exposed significant flaws in the existing legal and ethical structures governing vaccine development. The inequitable distribution of vaccines, where wealthier nations secured large stockpiles while developing countries struggled to access doses, highlights the urgent need for legal reforms to ensure fairer vaccine allocation mechanisms. The voluntary nature of initiatives like COVAX has proven insufficient, demonstrating the need for legally binding international agreements that prioritize public health over corporate profits. Ethically, vaccine development must adhere to the highest standards of informed consent, transparency, and public safety. The historical exploitation of vulnerable populations in clinical trials, such as the Pfizer Nigeria case, underscores the need for stricter ethical oversight in vaccine research. Governments and international bodies must ensure that ethical review boards are independent, well-funded, and empowered to enforce ethical guidelines. Furthermore, informed consent must be truly voluntary, without coercion or deception, particularly in developing nations where participants may not always have access to legal remedies in cases of misconduct. Transparency in clinical trials is equally essential; pharmaceutical companies should be legally required to disclose trial results, including negative findings, to prevent misinformation and build public trust.

One of the most contentious legal and ethical debates in vaccine development concerns vaccine mandates. Governments often impose mandatory vaccination policies to achieve herd immunity and prevent outbreaks, but these mandates raise questions of personal liberty and bodily autonomy. The landmark U.S. Supreme Court case Jacobson v. Massachusetts (1905) set the precedent that public health concerns can justify compulsory vaccination. However, modern societies demand a more nuanced approach, particularly in democratic nations where individual rights are constitutionally protected. The COVID-19 vaccine mandates faced significant legal challenges in both the United States and India, with courts recognizing the importance of public health but also affirming that coercive vaccination policies must be proportional and justified by compelling state interests. This ongoing debate suggests that future vaccine policies should focus on incentives rather than coercion, using strategies like public awareness campaigns, employer-based encouragement, and social responsibility initiatives rather than strict mandates. Another significant challenge is the role of misinformation in vaccine hesitancy, which has become a global public health crisis. The rise of social media-driven conspiracy theories about vaccine safety, fueled by unverified claims and politically motivated narratives, has led to declining vaccination rates and preventable disease outbreaks. Governments and health agencies have a moral and legal responsibility to combat misinformation while ensuring freedom of speech is not unduly restricted. However, there is a fine line between regulating harmful misinformation and protecting democratic discourse. Therefore, instead of outright censorship, governments should focus on fact-checking mechanisms, public health campaigns, and collaboration with social media platforms to reduce the spread of false information. Countries like Germany and France have introduced penalties for social media platforms that fail to regulate vaccine misinformation, a model that could be adopted globally.

The issue of vaccine affordability also poses a major ethical and legal dilemma. While pharmaceutical companies invest billions in research and development, should lifesaving vaccines be treated as a commercial commodity or a public good? The TRIPS Agreement and patent protections provide monopolistic control to vaccine manufacturers, often making vaccines unaffordable for many low-income nations. The COVID-19 pandemic exposed

these flaws, as developing nations struggled to obtain vaccines due to the high costs and limited supply caused by patent restrictions. While mechanisms like compulsory licensing and voluntary patent-sharing initiatives exist, they have rarely been effectively utilized in the vaccine industry. Future legal frameworks should create exceptions for public health emergencies, allowing faster, more affordable production of vaccines through temporary suspension of patent protections. This approach could prevent vaccine hoarding by wealthier nations and ensure that all countries have equitable access to critical immunization resources. Looking ahead, international cooperation in vaccine development must be strengthened. The COVID-19 pandemic demonstrated that no country can single-handedly combat global health crises, yet nationalistic policies often took precedence over collaborative efforts. Future pandemics require stronger global agreements on vaccine production, distribution, and pricing, ensuring that life-saving medical advancements are accessible to all, not just those who can afford them. Organizations like the WHO and WTO must work with governments to create legally binding agreements that prevent vaccine nationalism and ensure a fair distribution of resources. Finally, vaccine research itself must evolve ethically and transparently. With advancements in mRNA technology, AI-driven drug discovery, and personalized medicine, ethical considerations will continue to evolve. The use of AI in vaccine development raises concerns about data privacy, algorithmic bias, and ethical decision-making in drug trials. Future policies must ensure that emerging technologies adhere to the same ethical and legal standards as traditional vaccine research, with strong oversight mechanisms to prevent misuse. Additionally, clinical trials should be diversified to include broader population groups, ensuring that vaccines are effective across different ethnicities, age groups, and genetic profiles. In the way forward, vaccine development is not just a scientific endeavour but a legal and ethical balancing act. While vaccines remain one of humanity's greatest medical achievements, their development, distribution, and administration must adhere to principles of fairness, transparency, and accessibility. Future reforms should focus on strengthening ethical oversight in clinical trials, revising intellectual property laws to promote vaccine equity, implementing legal safeguards against misinformation, and ensuring global cooperation in vaccine research. By addressing these challenges, we can create

a more just, effective, and trustworthy vaccine development system that prioritizes public health over profit and ensures that no one is left behind in the fight against preventable diseases.

REFERENCES

Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299.

AstraZeneca India. (2021). *COVID-19 vaccine trials in India: Ethical and legal concerns*. https://www.astrazeneca.com/media-centre/articles/2021/clinical-trial-transparency.html

Centers for Disease Control and Prevention (CDC). (2022). *The impact of misinformation on vaccine hesitancy: A systematic review*. https://www.cdc.gov/vaccinesafety/concerns/misinformation.html

Central Drugs Standard Control Organization. (2021). *Regulatory approval process for COVID-19 vaccines in India*. Government of India. https://cdsco.gov.in/

Cohen, J. (2021). *Vaccine mandates and public health: The role of legal frameworks in infectious disease control. The Lancet Public Health, 6*(2), e136-e145. https://doi.org/10.1016/S2468-2667(21)00032-7

European Medicines Agency. (2021). *Guidance on approval processes for COVID-19 vaccines in the European Union*. https://www.ema.europa.eu/en/news/covid-19-vaccines-key-facts

European Medicines Agency. (2021). *Pharmacovigilance and post-market safety monitoring of vaccines*. https://www.ema.europa.eu/en/pharmacovigilance

Garrison, C., & Towse, A. (2020). *Patent pooling and the pandemic: Lessons from COVID-19*. *Journal of Law and the Biosciences, 7*(1), 1-13. https://doi.org/10.1093/jlb/lsaa065

Gostin, L. O., & Hodge, J. G. (2020). *The legality of mandatory vaccination for COVID-19: Balancing public health and civil liberties*. *New England Journal of Medicine, 383*(6), 403-406. https://doi.org/10.1056/NEJMp2022665

India Patent Act, 1970, § 84 (Compulsory Licensing Provisions).

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). (2021). *Vaccine production and intellectual property rights: Balancing innovation and access*. https://www.ifpma.org/resource-centre/intellectual-property-and-covid-19-vaccines/

Kumar, S., & Choudhury, P. (2021). *Legal perspectives on COVID-19 vaccine patents: A review of India's compulsory licensing provisions*. *Indian Journal of Law and Technology, 17*(1), 45-62

Mariner, W. K., Annas, G. J., & Glantz, L. H. (2005). *Jacobson v. Massachusetts: It's not your great-great-grandfather's public health law. American Journal of Public Health, 95*(4), 581-590. https://doi.org/10.2105/AJPH.2004.055160

National Childhood Vaccine Injury Act (NCVIA), 42 U.S.C. §§ 300aa-1 to 300aa-34 (1986).

Pfizer Inc. (2009). *In re Pfizer Trovan case: Ethical violations in Nigerian clinical trials*. New York: Pfizer Legal Archive.

Supreme Court of India. (2022). *Jacob Puliyel v. Union of India*, WP (C) 607/2021.

U.S. Food and Drug Administration. (2020). *Emergency use authorization for vaccines explained*. https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained

World Health Organization. (2021). *Guidelines on clinical evaluation of vaccines: Regulatory expectations*. WHO. https://www.who.int/publications/i/item/9789240027045

World Health Organization. (2022). *COVAX: The global initiative for equitable vaccine distribution.* https://www.who.int/initiatives/act-accelerator/covax

World Trade Organization. (2021). *TRIPS waiver proposal: Legal and economic implications for vaccine access*. https://www.wto.org/english/tratop_e/trips_e/covid19_e.htm

.

CHAPTER 2

THE RELEVANCE OF PHARMACOKINETICS TO VACCINES DEVELOPMENT

[1]Bello Hassan ONIMISI

[1]Mountain Top University, Chemical Science, Nigeria.

INTRODUCTION

According to Poland et al (2018), the vaccine is a biological preparation that provides active acquired immunity to a particular disease. there basically, live-attenuated vaccine, inactivated vaccine, subunit, recombinant, polysaccharide, and conjugate vaccine and toxoid vaccine. Moreso, Plotkin, Mortimer & Vaccines(1988) opined that Vaccines help protect millions of healthy people, likewise, they are considered as the most economical and effective preventive measure against the deadliest infectious diseases.

1. HISTORY OF VACCINES

Epidemics of smallpox swept across Europe in the seventeenth and eighteenth centuries, accounting for as much as 29% of the death rate of children in London. Initial efforts to control the disease led to the practice of variolation, which was introduced to England by Lady Mary Wortley Montagu in 1722, having been used in the Far East since the mid-1500s. In variolation, material from the scabs of smallpox lesions was scratched into the skin in an attempt to provide protection against the disease. Variolation did seem to induce protection, reducing the attack rate during epidemics, but sadly some of those who were variolated developed the disease and sometimes even died. It was in this context that Edward Jenner wrote 'An Inquiry into the Causes and Effects of the Variole Vaccinae…' in 1798. His demonstration, undertaken by scratching material from cowpox lesions taken from the hands of a milkmaid, Sarah Nelms, into the skin of an 8-year-old boy, James Phipps, who he subsequently challenged with smallpox, provided early evidence that vaccination could work. Jenner's contribution to medicine was thus not the technique of inoculation but his startling observation that milkmaids who had had mild cowpox infections did not contract smallpox, and the serendipitous assumption that material from cowpox lesions might immunize against smallpox. Furthermore, Jenner brilliantly predicted that vaccination could lead to the eradication of smallpox; in 1980, the World Health Assembly declared the world free of naturally occurring smallpox.

Almost 100 years after Jenner, the work of Louis Pasteur on rabies vaccine in the 1880s heralded the beginning of a frenetic period of development of new vaccines, so that by the middle of the twentieth century, vaccines for

many different diseases (such as diphtheria, pertussis and typhoid) had been developed as inactivated pathogen products or toxoid vaccines. However, it was the coordination of immunization as a major public health tool from the 1950s onwards that led to the introduction of comprehensive vaccine programmes and their remarkable impact on child health that we enjoy today. In 1974, the World Health Organization launched the Expanded Programme on Immunization and a goal was set in 1977 to reach every child in the world with vaccines for diphtheria, pertussis, tetanus, poliomyelitis, measles and tuberculosis by 1990. Unfortunately, that goal has still not been reached; although global coverage of 3 doses of the diphtheria–tetanus–pertussis vaccine has risen to more than 85%, there are still more than 19 million children who did not receive basic vaccinations in 2019.

2. TYPES OF VACCINES

The first human vaccines against viruses were based on using weaker or attenuated viruses to generate immunity, while not giving the recipient of the vaccine the full-blown illness or, preferably, any symptoms at all. For example, the smallpox vaccine used cowpox, a poxvirus similar enough to smallpox to protect against it, but usually didn't cause serious illness. Rabies was the first virus attenuated in a lab to create a vaccine for humans. Vaccines are made using several processes. They may contain live viruses that have been attenuated (weakened or altered to not cause illness); inactivated or killed organisms or viruses; inactivated toxins (for bacterial diseases where toxins generated by the bacteria, and not the bacteria themselves, cause illness); or merely segments of the pathogen (this includes both subunit and conjugate vaccines). Live, attenuated vaccines currently recommended as part of the U.S. Childhood Immunization Schedule include those against measles, mumps, and rubella (via the combined MMR vaccine), varicella (chickenpox), and influenza (in the nasal spray version of the seasonal flu vaccine). In addition to live, attenuated vaccines, the immunization schedule includes vaccines of every major type.

The different vaccine types each require different development techniques. Each section below addresses one of the vaccine types.

2.1 Live, Attenuated Vaccines

Attenuated vaccines can be made in several ways. Some of the most common methods involve passing the disease-causing virus through a series of cell cultures or animal embryos (typically chick embryos). Using chick embryos as an example, the virus is grown in different embryos in a series. With each passage, the virus becomes better at replicating in chick cells, but loses its ability to replicate in human cells. A virus targeted for use in a vaccine can be grown through—"passaged" through—upwards of 200 different embryos or cell cultures. Eventually, the attenuated virus will not replicate well (or at all) in human cells, and can be used in a vaccine. All the methods that involve passing a virus through a non-human host produce a version of the virus that can still be recognized by the human immune system, but cannot replicate well in a human host. When the resulting vaccine virus is given to a human, it will not replicate enough to cause illness, but will still provoke an immune response that can protect against future infection.

One concern that must be considered is the potential for the vaccine virus to revert to a form capable of causing disease. Mutations that can occur when the vaccine virus replicates in the body may lead to a more virulent strain. This is unlikely, as the vaccine virus's ability to replicate is limited. However, possible mutations are considered when developing an attenuated vaccine. It is worth noting that mutations are somewhat common with the oral polio vaccine (OPV), a live vaccine that is ingested instead of injected. The vaccine virus can mutate into a virulent form and lead to rare cases of paralytic polio. For this reason, OPV is no longer used in the United States, and has been replaced on the Recommended Childhood Immunization Schedule by the inactivated polio vaccine (IPV). Protection from a live, attenuated vaccine typically outlasts the protection provided by a killed or inactivated vaccine.

2.2 Killed or Inactivated Vaccines

One alternative to attenuated vaccines is a killed or inactivated vaccine. Vaccines of this type are created by inactivating a pathogen, typically using heat or chemicals such as formaldehyde or formalin. This destroys the pathogen's ability to replicate, but keeps it "intact" so that the immune system can still

recognize it. ("Inactivated" is generally used rather than "killed" to refer to viral vaccines of this type, as viruses are generally not considered alive.)

Because killed or inactivated pathogens can't replicate at all, they can't revert to a more virulent form capable of causing disease (as discussed above with live, attenuated vaccines). However, they tend to provide shorter protection than live vaccines, and are more likely to require boosters to create long-term immunity. Killed or inactivated vaccines on the U.S. Recommended Childhood Immunization Schedule include the inactivated polio vaccine and the seasonal influenza vaccine (injectable).

2.3 Toxoids

Most bacterial diseases are not caused by a bacterium itself, but by a toxin produced by the bacterium.for example, tetanus, immunizations for this type of pathogen can be made by inactivating the toxin that causes disease symptoms. As with organisms or viruses used in killed or inactivated vaccines, this can be done via treatment with a chemical, such as formalin, or by using heat or other methods.

Toxoids are vaccines produced from inactivated toxins. Toxoids can actually be considered killed or inactivated vaccines, but are sometimes given their own category to highlight that they contain an inactivated toxin, not an inactivated form of bacteria.

2.4 Subunit and Conjugate Vaccines

They both contain only pieces of the pathogens they protect against. But subunit vaccines use only part of a target pathogen to provoke a response from the immune system. This can be done by isolating a specific protein from a pathogen and presenting it as an antigen on its own. The acellular pertussis vaccine and influenza vaccine (in shot form) are examples of subunit vaccines.

Others are created through genetic engineering. This is done by using a gene coding for a vaccine protein and inserting it into another virus, or into producer cells in culture. When the carrier virus reproduces, or when the producer cell metabolizes, the vaccine protein is also created. The end result of this approach is a recombinant vaccine: the immune system will recognize the expressed protein and provide future protection against the target virus. A good

example of this is the Hepatitis B vaccine currently used in the United States is a recombinant vaccine.

Moreso, using genetic engineering, we can also develop the human papillomavirus (HPV) vaccine. There are two types of HPV vaccine —one provides protection against two strains of HPV, the other four—but both are made in the same way: for each strain, a single viral protein is isolated. When these proteins are expressed, virus-like particles (VLPs) are created. These VLPs contain no genetic material from the viruses and can't cause illness, but prompt an immune response that provides future protection against HPV.

Conjugate vaccines are somewhat similar to recombinant vaccines: they're made using two different components. Conjugate vaccines, they are made using pieces from the coats of bacteria. These coats are chemically linked to a carrier protein, and the combination is used as a vaccine. Conjugate vaccines are used to create a more powerful, combined immune response: typically, the "piece" of bacteria presented would not generate a strong immune response on its own, while the carrier protein would. The piece of bacteria can't cause illness, but combined with a carrier protein, it can generate immunity against future infection. The vaccines currently used for children against pneumococcal bacterial infections are made using this technique.

2.5 mRNA Vaccines

In 2020, as the COVID-19 pandemic was well underway, the United States and other countries around the world raced to create a vaccine against the SARS CoV-2 virus, the virus causing the pandemic. In the United States, "Operation Warpspeed" provided billions of dollars in funding to numerous pharmaceutical companies to develop a successful vaccine and take it to market. Under normal circumstances, the vaccine trials would have happened subsequently (i.e. phase I, phase II, phase III, etc.). Because of the public health emergency, vaccine trials occurred consecutively (phases I, II and III simultaneously).

Two vaccines were authorized for emergency use by the end of 2020 in the United States, both based on mRNA technology. (A third vaccine would be authorized early in 2021, based on viral vectors) This technology uses mRNA enveloped in a lipid (fat) sphere. The vaccine is then introduced into the body,

where the body's immune cells take up the vaccine particles and reveal the mRNA. The mRNA gives the cell "code" to create a protein similar to the "spike" protein on the coronavirus' surface. The immune cell then releases that protein to other immune cells, triggering an immune response that includes antibody production and activation of specialized cells to find and kill coronaviruses bearing that spike protein and any host cells infected.

2.6 Viral Vector

In early 2021, a third vaccine for the COVID-19 pandemic was authorized for use in the United States. That vaccine used a simian adenovirus that was basically hollowed out and the mRNA for coding a coronavirus spike protein was put inside. Like the mRNA vaccines, the mRNA in the viral vector is introduced into immune cells after those immune cells take up the simian adenovirus after recognizing it as a pathogen. The immune cell then creates the spike protein and triggers the ensuing immune response.

3. PHARMACOKINETIC PARAMETERS FOR VACCINES

From general pharmaceutical knowledge, Pharmacokinetic (PK) (also called Absorption, Distribution, Metabolism and Elimination (ADME)) studies are essential part of drug development. They involve the determination of all features related to drug kinetics including dose ranging and dose correlation with biodistribution, residence time in each organ, target exposure, and clearance pathways. inter- and intra-patient variability in drug kinetics undoubtedly exists, and the same dose of a given drug will produce a range of drug exposure profiles among a treated population. In pharmacological sense, PK studies provide a mathematical basis to define administration routes and methods, and determine a specific dosage regimen for each population strata to ensure safety and efficacy. Hence, PK studies are essential for maximizing clinical benefit while minimising variability and adverse effects. The wealth of accumulated historical experience with vaccines and due to the fact that the administered vaccine material is in most cases localized at the site of administration (with minimal distribution) and functions as a hub to which immunocytes are recruited and then promptly trigger a cascade of ensuing immunogenic processes. From records that is available, no biodistribution

studies on the active vaccine material per se are required unless a new formulation, different administration route or adjuvant are used. Despite the lack of regulatory harmonization among various countries, many regulatory agencies follow the guidelines provided by the World Health Organization (WHO), which do not consider PK studies on the biodistribution of the active vaccine material as a prerequisite for clinical approval before marketing, Plitnick (2013). According to Guideline on Clinical Evaluation of New Vaccines in 2005, WHO advise that PK studies, defined as determining serum or tissue concentrations of vaccine components, are normally not needed and should be considered on a case-by-case basis depending on the introduction of new adjuvants or formulations. Moreso, US Food and Drug Administration. Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry 2020, recommend similar guidelines to those provided by the WHO for traditional vaccines, the FDA specify that studies on the biodistribution of DNA vaccines can be waived if the vaccines are produced using previously approved vectors. Still, there is no FDA requirement for studying the biodistribution of expressed epitope(s).

According to Shen et al (2016), most biological processes are combined from aggregation of many small processes. Variations in the dynamics of biological processes depend on numerous small-scale subcomponents of the biological phenomenon, and responses from drugs and vaccines are no exception. They undergo inherent fluctuations and can be described as normal "Gaussian" or lognormal distributions depending on the nature of each pharmacological process in a large population, Lacey et al (1997). Regardless of the actual type of distribution, all biological distributions come with variance values that correspond to the level of heterogeneity in the ensemble of the population.

The essential pharmacokinetic parameters that clinicians need to pay attention to are the absorption constant, volume of distribution, elimination constants etc are not in most cases available foe evaluation before the vaccines is thrown into the market for sale. This is because most often than not these parameters are not easy to be conform uniformly because variabilities in human. This is also the major reason why their failures on the part of vaccines in some population. For example, in 2020, during the covid19 era, the covid

vaccines were found to have adverse effect on some patients or group of patients after taking the dose.

In conclusion, future vaccine development should make pharmacokinetic as an essential part if it must help in reducing the burden of disease.

REFERENCES

Guideline on Clinical Evaluation of New Vaccines EMEA/CHMP/ VWP/164653/2005. https:// www. ema. europa. eu/ en/ docum ents/scien tific- guide line/ guide line- clini cal- evalu ation- new- vacci nes_en. pdf.

Haber P, Amin M, Ng C, Weintraub E, McNeil MM. Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the vaccine adverse event reporting system(VAERS), 2008-2016. Hum Vaccin Immunother. 2018;1–5. doi:10.1080/21645515.2018.1491509.

Hotez PJ, Bottazzi ME, Strych U. New vaccines for the world‘s poorest people. Annu Rev Med. 2016;67:405–17. doi:10.1146/ annurev-med-051214-024241.

Lacey LF, Keene ON, Pritchard JF, Bye A. Common noncompartmental pharmacokinetic variables: are they normally or lognormally distributed? J Biopharm Stat. 1997;7(1):171–8. https://doi. org/ 10. 1080/ 10543 40970 88351 77.

Plitnick LM. Global Regulatory Guidelines for Vaccines. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. 2013;225-241. doi:https:// doi. org/ 10. 1016/ B978-0- 12-394810- 6. 00009-5

Plotkin, S.A., Mortimer, E. Vaccines. New York: Harper Perennial; 1988.

Plotkin, S.A., Orenstein, W.A., Offit, P.A., eds. Vaccines. 6th. ed. Philadelphia: Elsevier; 2013.

Poland GA, Kennedy RB, Ovsyannikova IG, Palacios R, Ho PL,Kalil J. Development of vaccines against Zika virus. Lancet Infect Dis. 2018;18:e211–e9. doi:10.1016/S1473 3099(18)30063-X.

Remington: The Science and Practice of Pharmacy – 1 Jun. 2005 by David B. Troy (Editor)

Shen M, Russek-Cohen E, Slud EV. Checking distributional assumptions for pharmacokinetic summary statistics based on simulations with compartmental models. J Biopharm Stat.2017;27(5):756–72. https:// doi. org/ 10. 1080/ 10543 406. 2016.12225 35.

Understanding mRNA COVID-19 Vaccines. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html

US Food and Drug Administration. Development and Licensure of Vaccines to Prevent COVID-19. Guidance for Industry. June 2020. https:// www. fda. gov/ regul atory- infor mation/ search- fda- guida ncedocuments/ devel opment- and- licen sure- vacci nes- preve nt- covid- 19

WHO Technical Report Series, No. 927, 2005 Annex 1- WHO guidelines on nonclinical evaluation of vaccines https:// www. who.int/ publi catio ns/m/ item/ annex1- noncl inical. p31- 63

CHAPTER 3

HUMAN PAPILLOMAVIRUS VACCINATION AND CERVICAL CANCER RISK

[1]R.VIDHYALAKSHMI
[1]G. PRATHEEBA
[2]C. REJITHA
[3]Prof. Dr. R.SRINIVASAN
[4]Assoc. Prof. Dr. Demet ÇELEBI

[1]Bharath Institute of Higher Education and Research, Tamil Nadu,Chennai.
[2]Bharath Institute of Higher Education and Research. Department of Pharmacology. Faculty of Pharmacy, Selaiyur, Chennai.
[3]Bharath Institude Of Higher Education and Research, Department of Pharmacology Faculty of Pharmacy, Selaiyur, Chennai
[4]Atatürk University Faculty of Veterinary Medicine and Vaccination Application and Research Center Deputy Director, 0000-0002-2355-0561

INTRODUCTION AND BACKGROUND: HUMAN PAPILLOMAVIRUS (HPV) AND CERVICAL CANCER

Human Papillomavirus (HPV) is a group of more than 200 related viruses, each consisting of a circular DNA genome that can infect the skin and mucous membranes. Among these, approximately 40 types of HPV are associated with infections in the genital area, and some of these can lead to cervical cancer. HPV is transmitted primarily through sexual contact, including vaginal, anal, and oral sex. While the majority of HPV infections do not result in any symptoms or serious health issues, certain high-risk strains of the virus are closely linked to the development of various cancers, including cervical cancer, one of the most common cancers in women worldwide. The relationship between HPV and cervical cancer has been well-documented over the past few decades, fundamentally altering the understanding of the disease and shaping prevention strategies. Cervical cancer, which originates in the cells of the cervix—the lower part of the uterus that connects to the vagina—remains one of the leading causes of cancer-related deaths among women, particularly in low- and middle-income countries where access to screening and medical interventions is limited. The introduction of the Pap smear in the mid-20th century was a groundbreaking step in early detection and prevention of cervical cancer. However, despite the success of screening programs, the burden of cervical cancer has not been fully eliminated. This is largely due to the persistence of HPV infection, which can go unnoticed for years without causing any symptoms.Human Papillomavirus is categorized into low-risk and high-risk strains based on their potential to cause cancer. Low-risk HPV types, such as HPV 6 and HPV 11, cause benign conditions like genital warts and respiratory papillomatosis. These types are not associated with the development of cervical cancer. On the other hand, high-risk HPV types, such as HPV 16 and HPV 18, are implicated in the majority of cervical cancer cases. These types can cause changes to the cells of the cervix, leading to precancerous lesions known as dysplasia. If these lesions are left untreated, they can progress into invasive cervical cancer over time. It is estimated that HPV infection is responsible for nearly 99% of all cases of cervical cancer, highlighting the virus's central role in the disease's development.The progression from a persistent HPV infection to cervical cancer is a multi-step process that typically

takes years. Most HPV infections, especially in young women, are cleared by the immune system within a couple of years. However, when the immune system fails to clear the infection, the virus can integrate its DNA into the host's genome, leading to the production of viral proteins that interfere with the normal functioning of the cell. These viral proteins, particularly E6 and E7, disrupt the cell cycle and can cause uncontrolled cell division, a hallmark of cancer. Over time, this unchecked growth may lead to the development of precancerous lesions and eventually invasive cancer if left undetected and untreated.The global burden of HPV-related cervical cancer is substantial. According to the World Health Organization (WHO), approximately 604,000 women were diagnosed with cervical cancer in 2020, and about 342,000 women died from the disease. While cervical cancer is most common in women aged 35 to 44, the impact of the disease is felt throughout a woman's life, affecting not only the patient but also families, communities, and healthcare systems. The incidence of cervical cancer is particularly high in regions with limited access to screening programs and medical treatment. In contrast, in countries with effective cervical cancer screening programs and widespread access to HPV vaccination, the incidence of cervical cancer has significantly decreased.The connection between HPV and cervical cancer has revolutionized the approach to prevention and treatment. HPV vaccines, developed in the early 2000s, have been one of the most significant advancements in cancer prevention. These vaccines are designed to protect against the most common high-risk HPV types, primarily HPV 16 and HPV 18, which are responsible for the majority of cervical cancer cases. The vaccines, such as Gardasil and Cervarix, have shown high efficacy in preventing infection with these high-risk strains and have been proven to dramatically reduce the risk of cervical cancer in vaccinated populations. Since their introduction, HPV vaccination programs have been implemented in many countries, particularly in adolescents and young women, with the goal of reducing the incidence of cervical cancer in future generations.Despite the promise of vaccination, there are significant challenges in ensuring equitable access to HPV vaccines and screening programs worldwide. High-income countries have seen substantial reductions in cervical cancer rates thanks to widespread vaccination and screening efforts, but many low- and middle-income countries still face barriers in accessing these

life-saving interventions. These barriers include limited healthcare infrastructure, lack of public awareness, cultural stigmas surrounding sexual health, and financial constraints. For instance, the cost of the HPV vaccine can be prohibitive in some regions, preventing many girls from receiving the vaccine before they are exposed to the virus.

Similarly, screening programs, such as Pap smears and HPV testing, require resources and trained healthcare personnel that may be lacking in some countries.In addition to vaccination and screening, other strategies for preventing cervical cancer have been developed. These include the use of condoms to reduce HPV transmission, although they do not offer complete protection since HPV can infect areas not covered by a condom. Also, advancements in molecular biology have led to the development of tests that can detect HPV infection and the presence of precancerous lesions more accurately. For example, HPV DNA testing can identify high-risk strains of the virus even in the absence of visible symptoms, allowing for earlier intervention.Treatment for cervical cancer typically involves a combination of surgery, radiation therapy, and chemotherapy, depending on the stage of the disease. Early-stage cervical cancer is often treatable with surgery alone, such as a hysterectomy (removal of the uterus) or a cone biopsy (removal of abnormal tissue from the cervix). For more advanced stages, radiation therapy and chemotherapy are used to target cancer cells. However, the prognosis for patients with advanced cervical cancer remains poor, emphasizing the importance of early detection and prevention.In conclusion, the relationship between Human Papillomavirus and cervical cancer is a critical area of research that has led to significant advances in prevention, diagnosis, and treatment. HPV is the primary cause of cervical cancer, and while most infections resolve on their own, persistent infection with high-risk strains can lead to the development of cancer. Vaccination, screening, and early intervention are essential in reducing the burden of cervical cancer worldwide. However, challenges remain, particularly in low-resource settings, and there is a continued need for global efforts to increase access to prevention and treatment services. With ongoing research, education, and healthcare improvements, the global fight against HPV-related cervical cancer holds promise for significantly reducing the incidence and mortality of this preventable disease in the future.



Fig:1 This diagram outlines the progression of cervical abnormalities from HPV infection to cervical cancer. It shows stages from CIN1 to CIN3 (cervical intraepithelial neoplasia) leading to invasive cancer if the infection persists over 1-10 years.

1. HPV VACCINE DEVELOPMENT AND COMPOSITION: A REVIEW OF CURRENT AND FUTURE VACCINES

The development of vaccines against Human Papillomavirus (HPV) has represented a significant milestone in global public health efforts to prevent cancer, specifically cervical cancer, and other HPV-related diseases. HPV is the most common sexually transmitted infection worldwide, and certain strains of this virus are responsible for various cancers, including cervical, anal, penile, and oropharyngeal cancers. For decades, the idea of an HPV vaccine was a dream, but with advances in molecular biology, virology, and vaccine technology, that dream has become a reality. HPV vaccination is now recognized as a critical tool in the fight against HPV-related cancers, with the potential to reduce the incidence of these diseases globally. In this review, we will explore the history of HPV vaccine development, the composition of current vaccines, and the future of HPV vaccination, focusing on the challenges and opportunities for improving vaccine efficacy, accessibility, and global coverage.

1.1 History of HPV Vaccine Development

The concept of creating a vaccine for HPV emerged from the growing recognition of the virus's association with cervical cancer and other malignancies. The identification of HPV as the causative agent of cervical cancer, especially high-risk types like HPV 16 and HPV 18, laid the foundation for vaccine development. In the late 1980s, researchers discovered that certain

HPV types had the ability to cause genetic alterations in host cells, leading to the development of precancerous lesions and, ultimately, invasive cancer. This discovery spurred a worldwide effort to develop vaccines that could prevent the infection from taking hold in the first place.The first major step in HPV vaccine development occurred in the early 1990s when researchers at the University of Queensland, led by Professor Ian Frazer, developed a method for producing virus-like particles (VLPs). These particles mimic the structure of the actual virus without containing its genetic material, making them ideal candidates for vaccine development. In 1993, the first generation of HPV vaccines was tested using VLP technology. These vaccines were found to be effective in eliciting an immune response capable of protecting against HPV infection, particularly the high-risk strains responsible for cervical cancer.In 2006, two HPV vaccines—Gardasil, developed by Merck, and Cervarix, developed by GlaxoSmithKline—were approved for use by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These vaccines targeted the two most common high-risk HPV types, HPV 16 and HPV 18, and were initially recommended for girls and young women between the ages of 9 and 26. The approval of these vaccines marked a major turning point in the fight against cervical cancer, as they offered the potential for nearly complete prevention of the disease.

1.2 Composition of Current HPV Vaccines

As of now, there are two main types of HPV vaccines available globally: the bivalent vaccine (Cervarix) and the quadrivalent vaccine (Gardasil), with a newer generation of vaccines that offer broader protection. These vaccines rely on the use of virus-like particles (VLPs) derived from the L1 protein of the HPV virus. The L1 protein is the major structural protein of the HPV capsid and is responsible for the virus's ability to infect host cells. When produced in a laboratory, VLPs form a structure that resembles the outer shell of the HPV virus, but they do not contain any viral DNA, meaning they cannot cause infection. When administered as a vaccine, these VLPs stimulate the immune system to produce antibodies that can neutralize the virus, preventing future infections.The bivalent vaccine, Cervarix, targets two high-risk HPV types, HPV 16 and HPV 18, which are responsible for approximately 70% of cervical

cancer cases worldwide. The quadrivalent vaccine, Gardasil, extends protection to two additional low-risk HPV types, HPV 6 and HPV 11, which are responsible for about 90% of genital warts cases. Both vaccines have shown high efficacy in preventing infection by the targeted HPV types, as well as the associated precancerous lesions and cancers, including cervical, anal, and vulvar cancers. Gardasil's inclusion of HPV 6 and HPV 11 also provides additional benefits in preventing genital warts, a condition that can cause significant psychological distress and discomfort.In 2014, Merck introduced an updated version of the Gardasil vaccine, known as Gardasil 9. This newer version extends protection to five additional high-risk HPV types: HPV 31, 33, 45, 52, and 58. These five strains, in addition to the original HPV 16 and 18, are responsible for a further 20% of cervical cancers, bringing the total coverage to around 90% of cervical cancer cases. Gardasil 9 has demonstrated high efficacy in preventing infections and precancerous lesions caused by these additional HPV types. The expanded coverage of Gardasil 9 marks a significant advancement in HPV vaccination, as it provides even broader protection against cervical and other HPV-related cancers.The vaccines are typically administered as a series of two or three injections, depending on the age of the recipient. For individuals aged 9 to 14, a two-dose schedule is recommended, with the second dose given 6 to 12 months after the first. For individuals aged 15 and older, a three-dose schedule is typically used. The vaccines are most effective when administered before any exposure to HPV, which is why they are recommended for pre-adolescent girls and boys, ideally around the age of 11 or 12. However, vaccination can still offer benefits to older individuals who have not yet been exposed to the virus.

1.3 Efficacy and Safety of Current HPV Vaccines

The efficacy of HPV vaccines has been extensively studied through clinical trials and real-world data. Clinical trials have shown that the vaccines are highly effective in preventing HPV infection, as well as the development of precancerous lesions and cancers caused by the targeted HPV types. For instance, studies have demonstrated that Gardasil provides protection against HPV 16 and HPV 18 infections for at least 10 years, with ongoing studies suggesting that the protection may last even longer.In terms of safety, HPV

vaccines have been shown to have an excellent safety profile. The most common side effects are mild and include pain at the injection site, redness, swelling, fever, and headaches. Serious side effects, such as allergic reactions, are rare. Extensive monitoring of the safety of HPV vaccines has been carried out by regulatory agencies, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). These organizations have found no significant evidence to suggest that the HPV vaccines cause long-term health problems. The benefits of vaccination in preventing cancer far outweigh the potential risks.

1.4 Future Directions in HPV Vaccination

As HPV vaccination continues to gain global acceptance, there are several areas where improvements and innovations can further enhance the impact of these vaccines. One of the main areas of interest is the development of a universal vaccine that targets all HPV types, including both high-risk and low-risk strains. Such a vaccine would provide broader protection against a wider range of cancers, including those caused by the less common high-risk types that are currently not covered by existing vaccines.Additionally, there is growing interest in developing a therapeutic HPV vaccine, which could be used to treat existing HPV infections and precancerous lesions. While current HPV vaccines are preventive, a therapeutic vaccine would aim to boost the immune system's ability to clear the virus from the body, potentially preventing the progression to cancer in individuals who are already infected with high-risk HPV types. Research in this area is still in the early stages, but promising results from preclinical and early-phase clinical trials suggest that a therapeutic vaccine could become an important tool in managing HPV-related diseases in the future.Another critical area for future vaccine development is improving access to HPV vaccination in low- and middle-income countries (LMICs), where the burden of HPV-related cancers is the highest. Cost remains a major barrier to widespread vaccination, particularly in resource-limited settings. Efforts to reduce vaccine prices, increase production capacity, and ensure that vaccines are delivered to underserved populations are essential for reducing global disparities in cervical cancer prevention. Additionally, public health campaigns aimed at raising awareness about the importance of HPV

vaccination and dispelling myths and misinformation can play a key role in increasing vaccination rates worldwide.Finally, ongoing surveillance and research into the long-term effectiveness of HPV vaccines are crucial. As vaccination coverage increases, it will be important to monitor the impact of HPV vaccination on population-level cervical cancer incidence and to assess whether booster doses may be needed to maintain immunity over time.The development of HPV vaccines represents one of the most important advancements in cancer prevention in modern history. By providing protection against the most common high-risk HPV types responsible for cervical cancer and other malignancies, these vaccines have the potential to save millions of lives globally. As new vaccines, such as Gardasil 9, continue to expand coverage and enhance protection, the goal of eliminating cervical cancer as a public health problem becomes increasingly achievable. However, challenges remain in ensuring equitable access to these vaccines, particularly in low-resource settings. With ongoing research, education, and global collaboration, the future of HPV vaccination looks promising, offering the hope of a world where HPV-related cancers are no longer a significant burden on public health.

2. HPV VACCINE EFFICACY AND SAFETY: A REVIEW OF CLINICAL TRIALS AND POST-LICENSURE STUDIES

Human Papillomavirus (HPV) vaccines represent a monumental advancement in the field of public health, offering the potential to significantly reduce the incidence of cervical cancer and other HPV-related malignancies. HPV, a group of more than 200 viruses, includes several high-risk strains, such as HPV 16 and HPV 18, which are responsible for the majority of cervical cancer cases. The development and introduction of HPV vaccines have marked a turning point in cancer prevention. However, their success is contingent on their efficacy, safety, and the monitoring of their impact post-licensure. This review seeks to provide a comprehensive analysis of the efficacy and safety of HPV vaccines based on clinical trials and post-licensure studies, highlighting both the successes and challenges in achieving widespread vaccination coverage.

Efficacy of HPV Vaccines: Clinical Trials and Early Data: The efficacy of HPV vaccines has been thoroughly evaluated in clinical trials, which have provided the scientific basis for the approval of these vaccines for public use. The initial clinical trials for HPV vaccines focused on evaluating the ability of the vaccine to prevent infection with HPV types responsible for the majority of cervical cancers and other HPV-related diseases. These vaccines, including Gardasil (Merck) and Cervarix (GlaxoSmithKline), were tested primarily in females aged 16 to 26, who were considered to be the most at-risk group for acquiring HPV infections.

Gardasil and Cervarix: Pre-licensure Studies:Gardasil, the first HPV vaccine to be approved by the U.S. Food and Drug Administration (FDA) in 2006, was evaluated in a series of large-scale randomized clinical trials involving over 20,000 participants across multiple countries. These trials demonstrated that Gardasil provided nearly 100% protection against persistent infection and cervical precancers caused by HPV types 16 and 18, which are responsible for approximately 70% of cervical cancers. In addition to HPV 16 and 18, Gardasil also provided protection against HPV types 6 and 11, which cause genital warts and respiratory papillomatosis.

Cervarix, approved shortly after Gardasil in 2007, targeted the same high-risk HPV types (HPV 16 and 18) but did not include the protection against HPV types 6 and 11. The clinical trials for Cervarix demonstrated similar high efficacy in preventing HPV 16- and 18-related cervical cancers and precancers. In these trials, Cervarix also showed a strong immune response and long-term protection, with evidence suggesting that protection may last for at least 10 years.Both vaccines were shown to be highly effective in preventing the development of high-grade cervical intraepithelial neoplasia (CIN), a precancerous condition that can lead to cervical cancer if left untreated. Additionally, they demonstrated efficacy in preventing other HPV-related cancers, including anal, vulvar, and vaginal cancers, as well as genital warts.

Gardasil 9: Extending the Scope of Protection:In 2014, Merck introduced Gardasil 9, an updated version of the original Gardasil vaccine. Gardasil 9 extended the protective coverage by targeting five additional high-risk HPV types (31, 33, 45, 52, and 58), which account for an additional 20% of cervical cancers. This expansion made Gardasil 9 capable of preventing up

to 90% of cervical cancers, as well as other HPV-related cancers.The clinical trials for Gardasil 9 showed that the vaccine was highly effective in preventing infections and precancers caused by these additional HPV types. In a trial involving more than 14,000 women, Gardasil 9 was found to be nearly 97% effective in preventing cervical, vulvar, and vaginal cancers caused by the nine HPV types targeted by the vaccine. Importantly, Gardasil 9 demonstrated safety and efficacy even in individuals who had already been exposed to one or more of the HPV types included in the vaccine, further enhancing its public health value.

Clinical trials have also assessed the efficacy of HPV vaccines in populations beyond the original target group of young women. For example, studies have shown that HPV vaccines are effective in preventing HPV-related diseases in males. Males can also be carriers of HPV and are at risk for HPV-related cancers, including penile, anal, and oropharyngeal cancers. In 2009, Gardasil was approved for use in males to prevent genital warts and anal cancer, and later, Gardasil 9 was approved for males as well.Moreover, the vaccines have been shown to be effective in older age groups. While vaccination is most effective when administered before any exposure to HPV, studies have indicated that even women who are older than the ideal target age (e.g., 26 and above) can benefit from vaccination, particularly if they have not been exposed to all the HPV types included in the vaccine.

Safety of HPV Vaccines: Clinical Trials and Post-Licensure Monitoring:The safety of HPV vaccines has been rigorously assessed throughout their development and post-licensure phases. In clinical trials, the vaccines were shown to have a favorable safety profile, with side effects primarily being mild and short-lived. Common side effects include pain at the injection site, swelling, fever, and headaches, similar to those seen with other vaccines. Serious side effects, such as allergic reactions, are rare.

Post-Licensure Surveillance*:* After HPV vaccines were introduced into the market, post-licensure surveillance was established to monitor the long-term safety of the vaccines in the general population. In the United States, the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) have been key tools for tracking vaccine safety. These systems have collected large amounts of data on the adverse events associated with HPV

vaccination, and the findings have been consistently reassuring. Serious adverse events, such as anaphylaxis or Guillain-Barré syndrome, have occurred at rates comparable to those seen with other vaccines and are extremely rare.One concern that emerged after the introduction of HPV vaccines was the potential for an increased risk of autoimmune disorders or neurological conditions. However, extensive studies and surveillance have found no consistent evidence linking the HPV vaccine to these conditions. For example, a study published in the Journal of the American Medical Association (JAMA) in 2018 reviewed data from several large studies and concluded that there was no increased risk of autoimmune diseases, including multiple sclerosis, after receiving the HPV vaccine. Similarly, research has shown no increased risk of ovarian failure or other reproductive health issues related to the vaccine.

2.1 Global Impact of HPV Vaccination

The widespread use of HPV vaccines has had a significant impact on reducing the incidence of HPV-related diseases, particularly cervical cancer, in countries with high vaccine coverage. In countries with comprehensive vaccination programs, such as Australia, where the vaccine was introduced in 2007, there have been marked reductions in the prevalence of HPV infections and cervical precancers. A study conducted in Australia found that HPV vaccination reduced the prevalence of HPV 16 and 18 in young women by more than 90%. Furthermore, the incidence of cervical cancer in vaccinated cohorts has been lower compared to those who were not vaccinated, demonstrating the vaccine's effectiveness in a real-world setting.In addition to Australia, other countries, including several European nations, Canada, and the United States, have experienced similar reductions in HPV-related diseases following the introduction of vaccination programs. These successes have provided strong evidence for the effectiveness and safety of the vaccines, and have encouraged other countries to adopt HPV vaccination as part of their routine immunization schedules.However, there remain significant challenges in implementing vaccination programs in low- and middle-income countries (LMICs), where the burden of HPV-related cancers is highest. The cost of the vaccine and lack of infrastructure to deliver it to hard-to-reach populations remain significant barriers. Efforts are ongoing to address these challenges through initiatives like

the Global Alliance for Vaccines and Immunization (GAVI), which works to reduce the cost of vaccines and increase access in LMICs.

While the HPV vaccine has been a remarkable success in reducing the burden of HPV-related cancers, there are still challenges that need to be addressed. One of the primary challenges is vaccine coverage. Although many high-income countries have high vaccination rates, coverage in low-income regions remains insufficient. Public education campaigns are critical to raising awareness about the benefits of vaccination, as misinformation and vaccine hesitancy remain significant obstacles to widespread uptake.Additionally, ongoing research is essential to ensure the long-term efficacy of the HPV vaccine. While the current vaccines provide protection against the most common cancer-causing HPV types, the development of a universal vaccine that targets all HPV types, including those not currently covered by existing vaccines, would further enhance the effectiveness of HPV vaccination programs. There is also the potential for therapeutic vaccines that could be used to treat existing HPV infections and associated precancerous lesions, which would represent a significant advancement in managing HPV-related diseases.The development and widespread use of HPV vaccines have proven to be a major success in the fight against cancer, especially cervical cancer, and other HPV-related diseases. Clinical trials and post-licensure studies have demonstrated that HPV vaccines are highly effective in preventing infection with the most high-risk HPV types, and they have a favorable safety profile. The introduction of Gardasil, Cervarix, and Gardasil 9 has dramatically reduced the incidence of HPV-related cancers, particularly in countries with strong vaccination programs. Post-licensure surveillance has further reinforced the safety of these vaccines, showing no significant long-term risks.While the impact of HPV vaccination has been overwhelmingly positive, challenges remain in ensuring equitable access to the vaccine, particularly in low-income countries. The success of HPV vaccination in reducing cancer rates and preventing infections underscores the importance of continuing to monitor vaccine safety, efficacy, and coverage in diverse populations, while also striving to overcome barriers to vaccination globally. With ongoing research and increased access to vaccines, the future of HPV vaccination holds the promise of significantly reducing the global burden of HPV-related cancers, ultimately

leading to the potential elimination of cervical cancer as a major public health threat.

3. REAL-WORLD IMPACT OF HPV VACCINATION ON CERVICAL CANCER RISK: OBSERVATIONAL STUDIES AND SURVEILLANCE DATA

Human Papillomavirus (HPV) vaccines have revolutionized the way the world approaches cervical cancer prevention. As the most effective tool to reduce the burden of this preventable disease, HPV vaccines have been a key strategy in global public health efforts. Since the introduction of the first HPV vaccines in the mid-2000s, numerous studies and long-term surveillance data have emerged, providing evidence that HPV vaccination reduces HPV infections, precancerous lesions, and, most importantly, cervical cancer itself. This review explores the real-world impact of HPV vaccination on cervical cancer risk, focusing on observational studies and surveillance data across various countries and regions. It examines how these vaccines have performed in diverse settings and how long-term monitoring has highlighted both successes and challenges.

3.1 Background of Cervical Cancer and HPV

Cervical cancer remains one of the leading causes of cancer-related deaths among women worldwide. Each year, an estimated 570,000 new cases of cervical cancer are diagnosed, and over 311,000 women die from the disease. Persistent infection with high-risk types of HPV, notably HPV types 16 and 18, accounts for approximately 70% of all cervical cancers. HPV is a common sexually transmitted infection, and although the majority of infections resolve on their own, some can persist and progress to cervical precancers, which can eventually evolve into invasive cervical cancer if left untreated.The introduction of the HPV vaccine has fundamentally changed the landscape of cervical cancer prevention. The first vaccines, Gardasil (2006) and Cervarix (2007), were designed to protect against the high-risk HPV types responsible for the majority of cervical cancers, particularly HPV 16 and 18. These vaccines also targeted other HPV types responsible for genital warts and other malignancies. Later, Gardasil 9, introduced in 2014, expanded protection to

include five additional high-risk HPV types (31, 33, 45, 52, and 58), further increasing the vaccine's potential to prevent cervical cancer.The success of HPV vaccination programs hinges on high vaccination coverage, and the real-world impact has been closely monitored through observational studies and long-term surveillance data. The following sections review the real-world effects of vaccination, drawing on data from several countries with robust vaccination programs.

3.2 Global Implementation of HPV Vaccination Programs

Countries that have implemented national HPV vaccination programs have provided valuable insight into the real-world impact of these vaccines. While the first countries to introduce HPV vaccines were mostly high-income nations, there has been significant progress in low- and middle-income countries (LMICs), where the burden of cervical cancer is highest.

Australia has been a pioneer in HPV vaccination and has consistently been at the forefront of cervical cancer prevention efforts. The country introduced its national vaccination program in 2007, initially offering the vaccine to girls aged 12-13. By 2013, the vaccination program was extended to include boys. Australia's commitment to HPV vaccination has paid off in remarkable ways. High vaccine coverage rates, combined with a strong screening program, have led to a significant decline in HPV infections and cervical cancer rates.In 2017, a landmark study published in The Lancet revealed a dramatic 86% reduction in HPV 16 and 18 prevalence in young women (aged 18-24) following the introduction of the HPV vaccine. Furthermore, another study published in The New England Journal of Medicine in 2019 demonstrated a 50% reduction in the incidence of high-grade cervical intraepithelial neoplasia (CIN), a precursor to cervical cancer. These reductions are among the first signs that HPV vaccination is making a tangible impact on cervical cancer prevention. The cervical cancer rate in young women has also dropped significantly. In 2017, the age-standardized rate of cervical cancer among women aged 20-24 fell by 51%, marking the first observable drop in cervical cancer rates in this age group in decades. These early results indicate that Australia is on track to achieve the World Health Organization's goal of eliminating cervical cancer as a public health problem by 2030.

The UK introduced its HPV vaccination program in 2008, initially targeting girls aged 12-13. In 2019, the program was expanded to include boys. The country has consistently achieved high vaccine coverage rates, with nearly 90% of girls aged 12-13 receiving the vaccine by 2019. Like Australia, the UK has seen a significant reduction in HPV infections and cervical precancers among vaccinated cohorts. A study published in The BMJ in 2018 found a 90% reduction in HPV 16 and 18 infections among vaccinated women compared to unvaccinated women. Additionally, research published in Lancet Public Health in 2020 found that the incidence of high-grade CIN in women under 25 had decreased by 50% in vaccinated cohorts, further solidifying the effectiveness of the vaccine in preventing precancerous lesions. The UK's experience has shown that national HPV vaccination programs can significantly reduce HPV-related disease burden, including cervical cancer precursors. With continued surveillance and monitoring, the country is expected to see even greater reductions in cervical cancer rates as the impact of vaccination extends to older age groups.

Sweden's HPV vaccination program, which began in 2012, has yielded encouraging results. The program initially targeted girls aged 11-12 and later expanded to include boys. By 2018, around 80% of girls had received at least one dose of the vaccine. A 2020 study conducted by researchers in Sweden demonstrated that the vaccine reduced the risk of cervical cancer-related lesions by 88% in young women who were vaccinated at age 10-12. These findings mirror the success seen in Australia and the UK and underscore the broader applicability of HPV vaccination in different population groups. Sweden's experience also highlights the importance of long-term follow-up in assessing the impact of vaccination on cervical cancer incidence.One of the primary goals of HPV vaccination is to prevent HPV infections, particularly those caused by high-risk types. Observational studies and surveillance data from countries with high vaccination coverage consistently show significant reductions in the prevalence of HPV infections. In countries such as Australia, the UK, and Sweden, the prevalence of HPV 16 and 18 among young women has declined by up to 90%, providing compelling evidence of the vaccine's effectiveness.Moreover, the reduction in HPV infections has translated into decreases in cervical precancers, particularly high-grade CIN, which is the most

common precursor to cervical cancer. Studies from these countries have shown reductions in the incidence of CIN by up to 50%, further supporting the long-term benefits of HPV vaccination. Since CIN lesions can take years or even decades to progress to invasive cervical cancer, the reduction in precancers provides a clear indication that HPV vaccination is effectively preventing the future burden of cervical cancer.While high-income countries have led the way in HPV vaccination, LMICs have seen growing momentum in their own vaccination efforts. In many of these countries, cervical cancer remains a major public health concern due to limited access to screening and treatment options. In response, several LMICs have introduced HPV vaccination programs, often with the support of global health organizations such as the World Health Organization (WHO) and GAVI, the Vaccine Alliance.

Rwanda is one of the first African countries to implement a national HPV vaccination program, which began in 2011. By 2016, the country achieved a remarkable 93% vaccination coverage among girls aged 12. Data from Rwanda show that the HPV prevalence among vaccinated cohorts has decreased, suggesting that the vaccine is effective in preventing HPV infections and, by extension, cervical cancer. Although Rwanda is still in the early stages of evaluating the long-term impact on cervical cancer incidence, the early data point to significant benefits. The success of Rwanda's HPV vaccination program serves as a model for other countries in sub-Saharan Africa, where cervical cancer rates are among the highest globally.

Mexico and Brazil have also made strides in implementing HPV vaccination programs. In Mexico, HPV vaccination was introduced in 2009, with vaccination coverage reaching around 85% by 2018. Early data from Mexico show a reduction in HPV infections and a decrease in the incidence of cervical precancers. Similarly, Brazil, which launched its HPV vaccination program in 2014, has seen positive results, with vaccination rates steadily increasing and early indicators of reduced HPV prevalence.The success of these countries in scaling up HPV vaccination programs underscores the feasibility of cervical cancer prevention in LMICs. However, challenges remain in achieving universal vaccination coverage, addressing logistical barriers, and increasing public awareness about the importance of vaccination.Despite the significant successes of HPV vaccination, challenges remain in achieving

widespread global impact. In LMICs, barriers such as vaccine cost, limited healthcare infrastructure, and lack of public awareness still hinder the successful implementation of vaccination programs. Increasing access to vaccines and reducing costs are critical to overcoming these obstacles.Moreover, as vaccine coverage increases, it will be crucial to continue surveillance to monitor the long-term impact of vaccination on cervical cancer rates. Although early data from countries with high vaccination rates are promising, it will take decades to fully assess the long-term effects of HPV vaccination on cervical cancer incidence.Another area of focus is the development of new vaccines. While Gardasil 9 has made significant strides in expanding protection against additional HPV types, future vaccines that offer broader protection and are more cost-effective will be essential to achieving universal cervical cancer prevention. Additionally, researchers are investigating therapeutic vaccines that could treat existing HPV infections and precancerous lesions, which would provide a new avenue for managing HPV-related diseases.The real-world impact of HPV vaccination on cervical cancer risk has been overwhelmingly positive, with substantial reductions in HPV infections, cervical precancers, and cervical cancer observed in countries with high vaccine coverage. Long-term surveillance and observational studies from countries such as Australia, the UK, Sweden, and Rwanda provide compelling evidence that HPV vaccination is effective in preventing cervical cancer. As vaccination programs continue to expand globally, particularly in low- and middle-income countries, the potential for reducing the burden of cervical cancer worldwide is immense. While challenges remain, the success of HPV vaccination programs worldwide provides hope that the goal of eliminating cervical cancer as a public health problem by 2030 is within reach. With continued investment in vaccination, surveillance, and public health initiatives, the global fight against cervical cancer can be won.

CONCLUSION AND FUTURE DIRECTIONS: MAXIMIZING THE IMPACT OF HPV VACCINATION ON CERVICAL CANCER PREVENTION

In conclusion, the widespread implementation of HPV vaccination has significantly advanced cervical cancer prevention by reducing the prevalence of high-risk HPV strains. Evidence highlights the vaccine's efficacy in preventing HPV infections that lead to cervical dysplasia and cancer, ultimately saving lives and reducing healthcare costs. However, to maximize the impact of vaccination, global efforts must focus on improving access to vaccines in low-resource settings, particularly in regions with high cervical cancer incidence. Educational campaigns aimed at increasing awareness, addressing vaccine hesitancy, and ensuring gender-neutral vaccination strategies are crucial. Additionally, continuous monitoring and research are essential to assess vaccine effectiveness over time and in diverse populations. Future directions should also explore the integration of HPV vaccination with cervical cancer screening programs, as well as the development of broader vaccines targeting a wider range of cancer-causing HPV strains. Collaborative international efforts will be key to eradicating cervical cancer globally.

REFERENCES

Anorlu RI (2008) Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin

Cancer tomorrow: estimated number of cervical cancer incidence and mortality in Ethiopia

Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet

De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP (2013) The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M et al (2012) Global burden of human papillomavirus and related diseases. Vaccine

Hull R, Mbele M, Makhafola T, Hicks C, Wang S-M, Reis RM, Mehrotra R, Mkhize-Kwitshana Z, Kibiki G, Bates DO et al (2020) Cervical cancer in low and middle-income countries. Oncol Lett Integrated Africa cancer factsheet focusing on cervical cancer

WHO: Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. In: World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland 2013.

World Health Organization (WHO). Cervical cancer. Available from . Accessed on 17 Aug 2022

CHAPTER 4

VACCINE FOR LEISHMANIASIS

[1]Arshan SHAFQAT
[2]Zohaib SAEED
[3]Saifullah RASHID

[1] Multan University of Science and Technology, Multan College of Veterinary Sciences, Multan Pakistan.
[2] Multan University of Science and Technology, Multan College of Veterinary Sciences, Multan Pakistan.
[3] Multan University of Science and Technology, Multan College of Veterinary Sciences, Multan Pakistan.

INTRODUCTION

Leishmania is an intracellular protozoan parasite which is responsible for a vector-borne disease called as leishmaniasis [1,2,3]. There are more than 30 species of leishmania protozoan known world widely for producing leishmaniasis of various kinds [4,5,6]. According to world health organization, about 350 million people are at risk of getting leishmaniasis [7,8,9]. The mainly effected hosts of leishmaniasis include humans, dogs, and some rodent [10]. Leishmaniasis in humans is mainly found in two forms i.e. cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL) [11,12]. Approximately there are 58,000 cases of visceral leishmaniasis and 220,000 cases of cutaneous leishmaniasis reported annually [13,14]. The morphology of almost all the leishmania species is same and appear as intracellular amastigote which is an ovoid usually 3-6µm long structure containing a nucleus or kinetoplast visible in stained preparation [15]. Promastigote is a spindle shaped structure which develops in the small intestine of the vector by transformation. Leishmaniasis is classified into two forms as new world Leishmaniasis and old world leishmaniasis on the basis of the vector involved in transmission [16,17]. *Leishmania* parasite of old world is transmitted by the bite of sandfly of genus phlebotomus in Europe, Africa, and Asia while the parasite of new world is transmitted by the sandfly of genus *Lutzomyia* in America [18,19]. There are over 30 species of sandfly which are involved in the transmission of leishmania parasite on the basis of which leishmaniasis is further classified into sub-species like *L.tropica, L.major, L.aethiopica, L.amazonesis, L.braziliensis* etc. Over the past years, many researches have been conducted for the development of vaccine against leishmania parasite but till now no effectively declared vaccine have been developed [20,21]. Although such researches involved the use of candidate antigens whom administration through different routes affect protective immunity and helps in immune response development but still the successful trail of such antigens in humans remained elusive. This purpose of this book chapter is to focus on providing an extensive overview of the ongoing advancement in leishmaniasis vaccine development.

1. IMMUNE RESPONSE AGAINST LEISHMANIA PARASITE

The fundamental role in the development of leishmania infection is played by the interaction between macrophages and the leishmania parasite [22]. Macrophages are the primary host for leishmania parasite and are crucial for survival, replication, and differentiation of the parasite. As macrophages are well- known for their characteristic engulfing and killing of foreign bodies but the leishmania parasite manipulates the killing mechanism of macrophages at the times of their entry and initiates the production of interleukins-4 and certain disease stimulating factors by T-cells which leads to progression of disease and survival of the parasite [23]. As soon as the parasite interferes with CD-40 pathway of the macrophages, it diverts thier pathway and affects the interaction between T cells and CD-40 receptors of macrophags and prevents them from developing the anti-parasitic pathway.

1.1 Vaccine Concept for Leishmaniasis

For the development of effective vaccine against leishmaniasis, there are many reasons to support its possibility. The development of such vaccine is very desirable because of an increased resistance to first line drug and the toxicity of second-line drugs. The advanrtages of using vaccine against leishmaniasis over chemotherapy are that they induce long-lasting effects and can be adminstered in both therapeutic and prophylactic modes [24]. Additionally, there will be no problem of facing resistance against vaccine as in the case of chemotherapy. The number of patents for leishmaniasis vaccine are 74 in US and 36 in brazil as stated in a study publication reported by Thomas-Soccol in 2018 [25]. There are 20,000 cases of leishmaniasis including 3,000 cases of VL in Brazil and 8,000 cases of VL in India. Spain and France are still endemic for VL as prevalence is 0.22 per 100,00 population in such regions [26]. Therefore, there is a need of vaccination against leishmaniasis in such regions.

1.2 Vaccination for Leishmania

The developing of an immune response against leishmania parasite was firstly observed by adler in which the labanese children whose arms were

exposed to mosquitoes by their mothers gets a protection against severe form of leishmania disease in the future [27]. The first known method of providing immunization against leishmaniasis was called leishmanization. It was developed in 1940 and was used in many countries for years. The method involves the intradermal injecting of live and active *L.Major* amastigote in the deltoid muscle which develops into an active ulcer and heals on its own. The method results in providing long term immunity against rural and urban leishmaniasis but was discountinued because of its low safety of margin.

2. FIRST GENERATION VACCINES

The first-generation vaccines contain the whole disease containing organism or parasite's body along with or without the adjuvants. These vaccines replaced the leishmanization and the vaccine is also used in human trails. They are categories into killed, live attenuated, and fractionated vaccines.

2.1. Killed Vaccines

These vaccines contain a whole dead parasite's body used for developing an immune response. Such killed vaccine was developed and *evaluated* in Brazil by Mayrink and his team in which the vaccine provides only 50% effectiveness against leishmania [28]. Another experiment was done by Sharples in which a mixture of killed *L. amazonesis ,L. Mexicana,* and *bacillus Calmet Guerin* as an adjuvant used to treat cutaneous leishmaniasis resulting in 95% effectiveness and activation of Th immunity. The results of the study conducted by Mehmoodi revealed that BCG + ALM containing vaccine have higher stimulation index and IFN levels than those containing only BCG [29]. In short vaccine containing killed leishmania organism can be considered as a safe, effective and economical treatment nevertheless it includes the adjuvants in its composition.

2.2 Live Attenuated Vaccines

Such vaccines include the organisms which are alive but their ability of causing disease- or disease-causing factor is either inhibited or reduced [30]. These vaccines are the current gold standard for treatment of leishmaniasis having a parasite which is both non-pathogenic and superior to killed parasites.

To prepare a live attenuated parasite, the methods include in-vitro culturing, use of temperature sensitivity, exposure to gamma radiation, chemical mutations, and culturing with antibiotics [31]. Such live attenuated vaccine was developed by Titus and his co-workers by knocking down certain leishmania genes

2.3 Fractionated Vaccines

Fractionated vaccines include the several molecules either membrane proteins like A2 or HASPB1 protein or soluble fractions of the parasite are used as a potential target for producing immune responses against both cutaneous and visceral leishmaniasis [32]. This kind of vaccine is advantageous because of its high yeild and purity.

Following gives some of the used first-generation vaccines in researches for vaccine production on both human and model animals:

- The live and pathogenic promastigotes of leishmania parasite are inserted in C57BL/6 rodents' strain for providing immunization through ear vial intradermal route or in the footpad vial sub-cutaneous tissues resulted in protection against cutaneous leishmaniasis caused by L.Major. *S*ub-cutaneous route provides more effective enhanced IFN and IL levels [33].
- A mixture of L. mexicana and L. major promastigotes which is long-termed cultured with gentamycin is inserted into BALB/c rodent' strain for providing immunization through sub-cutaneous injection resulted in protection against cutaneous leishmaniasis involving the lesion size to be reduced by 80% and reduction of infected macrophages [34].
- A mixture of L.donovani and L.infantum promastigotes which is long-termed cultured with gentamycin is inserted into BALB/c rodent' strain for providing immunization through sub-cutaneous injection resulted in protection against visceral leishmaniasis involving the infected macrophages to be reduced up to 99% [35].
- An attenuated antigen of L.chagasi containing the promastigotes is inserted into the BALB/c variant of rodent against the visceral leishmaniasis resulted in no protection as it faces the challenges with the virulence of promastigotes [36].

- A mutant promastigote along with Ipg2 adjuvants of L.major is inserted in the BALB/c variant of rodents resulted in providing the protection against cutaneous leishmaniasis caused by L.major [37]. Another outcome of this vaccine is supressed IL-10 and IL-4 production.
- CP mutant promastigotes of L.mexicana are inserted in the hamster resulted in providing protection against cutaneous leishmaniasis caused by L.mexicana another outcome of this vaccine is the high Interferons level [38].
- BTI knock-out promastigotes of L.donovani are inserted in BALB/c variant rodent resulted in providing protection against visceral leishmaniasis caused by L.donovani. Infection rate was reduced upto 75% with increased interferons-γ level and no IL-4 production [39].
- Non-pathogenic promastigotes of L.tarentolae are inserted in the BALB/c variant rodent resulted in providing protection against visceral leishmaniasis caused by L.donovani. Additional outcomes include 80-85% reduction in the parasite concentration, increased interferons production, no IL-4, and spleen cell proliferation increased by 17 folds [40].
- Porphyrogenic and non-porphyrogenic transfectants of L. amazonesis is inserted in hamster which resulted in providing protection against visceral leishmaniasis with the help of photodynamic vaccination along with transfectants. Other outcomes include 99% reduction of parasite, increased Delayed-typed hypersensitivity and lymphoproliferative response [41].
- The antigen of L. infantum is injected one millimeter of the fraction intracutaneously in four different points of the skin in both human and animal resulted in providing protection against cutaneous leishmaniasis [41].
- Ipg2-mutant promastigotes of L. major along with CpG oligonucleotides adjuvant is inserted in C57BL/6 model animal resulted in providing protection against cutaneous leishmaniasis caused by L. major. The additional outcomes include 100 fold parasite reduction, no IFN-γ productuion and Delayed-type hypersensitivity.

3. SECOND GENERATION VACCINES

Second generation vaccines for leishmaniasis are consists of synthetic or recombinant subunits, genetically modified leishmania strains, recombinant bacteria, or viruses carrying leishmania antigen genes [42]. These vaccines are made by genetical engineering for preventing the risks developed from using the whole live organism.

Following gives some of the genetically prepared vaccines developed in researches against leishmania parasite by using various animal model:

- *S. typhimurium* bacterial sub-specie of salmonella containing the gp63 antigen of leishmania parasite is inserted in the BALB/c model animal resulted in providing protection against cutaneous leishmaniasis caused by L. major. Other outcomes of the research include the efficacy of vaccine only in CBA mice, reduction of parasite up to 65% and activation of CD4 + T cells which secretes IFN-γ and IL-40 [43].
- The E. coli bacterium containing rgp63 antigen of leishmania parasite insertion in monkeys resulted in providing a partial protection from the cutaneous leishmaniasis caused by L. major [44]. Additional observation includes the positive delayed-type hypersensitivity, no production of IFN-γ and high IgM antibody level.
- Transfected BCG adjuvant along with rgp63 antigen inserted in the BALB/c model animals resulted in providing protection from cutaneous leishmaniasis caused by L. mexicana or L. major [45]. Protection against both the L. mexicana and L. major was developed in mouse strains with strong lymphoproliferative response.
- Cationic liposomes adjuvants containing the gp63 antigen inserted in the BALB/c model animal resulted in providing protection against visceral leishmaniasis caused by L. donovani [46]. Other outcomes include the reduction of parasite 86% and 81% in liver and spleen respectively, high level of IFN-γ, low IL-40 production and positive delayed-type hypersensitivity.
- Vaccinia virus adjuvant containing the GP46 or M-2 antigen inserted in BALB/c model animal resulted in providing a protection against cutaneous leishmaniasis caused by L. amazonesis. Additionally, IL-2, IFN- γ and IL-4 production along with high IgG1 and IgG2a levels [47].

- C.parvum adjuvant containing the PSA-2 antigen inserted in C3H/HE mice strain model animal resulted in providing protection against cutaneous leishmaniasis caused by L. major. High IFN-γ production and high IgG1 levels were observed as the additional outcomes of research [48].
- Saponin adjuvant containing FML antigen inserted in swiss albino model animal resulted in providing protection against visceral leishmaniasis caused by L. donovani. Other outcomes include the 85% reduction of parasite in liver and 80% increase in the antibody response.
- Saponin aluminum hydroxide adjuvant containing FML antigen inserted in swiss albino model animal resulted in protection agaimst visceral leishmaniasis along with 85% and 88% liver parasite reduction in FML+ saponin and FML+ Al(OH)3 respectively. Increased IgG2a level in the former group.
- QuilA containing the FML antigen inserted in dogs resulted in providing protection against visceral leishmaniasis. About 95% protection or efficacy is achieved through this vaccine including the positive delayed-type hypersensitivity [49].
- MDP containing the LiESA antigen in dogs resulted in providing protection against visceral leishmaniasis caused by L. infantum. Increased level of IgG2, enhanced IFN-γ , And no production of IL-40 is observed as additional outcome. This vaccine provides 92% efficacy

4. THIRD GENERATION VACCINES

Third generation vaccines are defined as those which utilizes the use of recombinant technologies for the production of vaccine against parasite [50]. DNA vaccines are third-generation vaccines which utilize the recombinant technologies for the production of leishmaniasis vaccine.

4.1 DNA Vaccines

Vaccines which contain plasmid DNA to encodes foreign proteins in the body after being injected are termed as DNA vaccines. This leads to the production of endogenous proteins and helps in generating immune response. DNA vaccines consist of heterologous DNA which produce antigenic proteins

and are supplied by vectors which allows them to express in the eukaryotic cells. These vaccines come in various forms including recombinant proteins, single vaccines and multigene forms. They have the ability to generate both the cell-mediated and humoral immunity. Many model organisms like mice, dogs, hamster etc. Are used for testing such vaccines against both the cutaneous and visceral leishmaniasis. DNA vaccines provide various advantages over other generation of vaccine for leishmaniasis as they are fast, simple and cheap producing vaccines. There is no requirement of low temperature, storage and specific transportation protocols for such vaccines. They have the ability to provide long-term protection and immunity against various strains of leishmania. The only problem faced by such vaccines is the risk of entering the parasite DNA in to the mammalian genome which carries the potential risk of developing cancerous and auto-immune diseases.

Following gives some of the DNA vaccines used in researches for the vaccination of leishmania parasite:

- gp63 antigen along with pCMV adjuvant is inserted in the BALB/c model animal which results in providing protection against cutaneous leishmaniasis. Enhanced IL-12 and IFN-γ production is observed as other outcomes [51].
- VR1012 adjuvant along with gp63 or gp46 is inserted in the BALB/c model animal which results in providing partial protection against cutaneous leishmaniasis caused by L. mexicana [52]. 100-fold parasite and 30% reduction in lesion size is observed.
- pcDNA3 adjuvant along with A2 antigen is inserted in BALB/c model animal which results in providing protection against both cutaneous and visceral leishmaniasis caused by L. amazonensis / L. chagasi [53].

CONCLUSION

In conclusion, it is crucial to develop am effective vaccines against leishmaniasis in order to reduce the burden of this complex protozoal parasitic disease. From the recent years, various significant progress has been made in the development of an effective vaccine despite of the challenges associated with such productions. The development of such vaccine will require a continued study in researches and collaboration between scientists and industry

partners. Although there are many research conducted on developing leishmania parasite vaccine using different generations but still there is a need to improve the immunogenicity, efficacy and safety of the vaccine in order to overcome the obstacles related to vaccine development. DNA vaccines have those characteristic properties and advantages of safety, efficacy and immunogenicity over other generation of vaccines of leishmaniasis but it suffers with the risk factors of cancerous and auto-immune diseases. Ultimately, these vaccines should have the potential to improve the health and well-being of people for which we have to continue research.

REFERENCES

Abdellahi L, Iraji F, Mahmoudabadi A, Hejazi SH. Vaccination in leishmaniasis: A review article. Iranian Biomedical Journal. 2021 Dec 20;26(1):1.

Abdellahi L, Iraji F, Mahmoudabadi A, Hejazi SH. Vaccination in leishmaniasis: A review article. Iranian Biomedical Journal. 2021 Dec 20;26(1):1.

Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, Sereno D. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS neglected tropical diseases. 2016 Mar 3;10(3):e0004349.

Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, Sereno D. A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS neglected tropical diseases. 2016 Mar 3;10(3):e0004349.

Alemayehu B, Alemayehu M. Leishmaniasis: a review on parasite, vector and reservoir host. Health Science Journal. 2017 Aug;11(4):1.

Alemayehu B, Alemayehu M. Leishmaniasis: a review on parasite, vector and reservoir host. Health Science Journal. 2017 Aug;11(4):1.

Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Boer MD, WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PloS one. 2012 May 31;7(5):e35671.

Aunguldee T, Wongsatayanon B. *Immunogenicity of Cysteine Protease Leishmania Martiniquensis DNA Based Vaccine in Mice* (Doctoral dissertation, Srinakharinwirot University).

Aunguldee T, Wongsatayanon B. *Immunogenicity of Cysteine Protease Leishmania Martiniquensis DNA Based Vaccine in Mice* (Doctoral dissertation, Srinakharinwirot University).

Bhattacharya S, Bohara VS, Sevda S, Kumar S. Vaccine and vaccine types. InBioreactor Design Concepts for Viral Vaccine Production 2024 Jan 1 (pp. 73-82). Academic Press.

Borja-Cabrera GP, Mendes AC, de Souza EP, Okada LY, de A Trivellato FA, Kawasaki JK, Costa AC, Reis AB, Genaro O, Batista LM, Palatnik M.

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine. 2004 Jun 2;22(17-18):2234-43.

Crampton A, Vanniasinkam T. Parasite vaccines: the new generation. Infection, Genetics and Evolution. 2007 Sep 1;7(5):664-73.

de Oliveira AH, Ruiz JC, Cruz AK, Greene LJ, Rosa JC, Ward RJ. Expression in E. coli and purification of the nucleoside diphosphate kinase b from Leishmania major. Protein expression and purification. 2006 Oct 1;49(2):244-50.

de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. American journal of clinical dermatology. 2015 Apr;16:99-109.

Desjeux P. The increase in risk factors for leishmaniasis worldwide. Transactions of the royal society of tropical medicine and hygiene. 2001 May 1;95(3):239-43.

Glew RH, Saha AK, Das SI, Remaley AT. Biochemistry of the Leishmania species. Microbiological reviews. 1988 Dec;52(4):412-32.

Gorham JD, Guler ML, Fenoglio D, Gubler U, Murphy KM. Low dose TGF-β attenuates IL-12 responsiveness in murine Th cells. The Journal of Immunology. 1998 Aug 15;161(4):1664-70.

Haftom M, Petrucka P, Gemechu K, Nesro J, Amare E, Hailu T, Ashebir Y, Gebreheat G, Hagos H, Gebremedhin D, Gebremariam A. Prevalence and risk factors of human leishmaniasis in Ethiopia: a systematic review and meta-analysis. Infectious Diseases and Therapy. 2021 Mar;10:47-60.

Handman E. Leishmaniasis: current status of vaccine development. Clinical microbiology reviews. 2001 Apr 1;14(2):229-43.

Karamysheva ZN, Gutierrez Guarnizo SA, Karamyshev AL. Regulation of translation in the protozoan parasite leishmania. International journal of molecular sciences. 2020 Apr 23;21(8):2981.

Klatt S, Simpson L, Maslov DA, Konthur Z. Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host. PLoS neglected tropical diseases. 2019 Jul 25;13(7):e0007424.

Lachaud L, Dedet JP, Marty P, Faraut F, Buffet P, Gangneux JP, Ravel C, Bastien P, the Working Group for the Notification of Human

Leishmanioses in France C. Surveillance of leishmaniases in France, 1999 to 2012. Eurosurveillance. 2013 Jul 18;18(29).

Lafleur A, Olivier M. Viral endosymbiotic infection of protozoan parasites: How it influences the development of cutaneous leishmaniasis. Plos Pathogens. 2022 Nov 3;18(11):e1010910.

Liu D, Uzonna JE. The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response. Frontiers in cellular and infection microbiology. 2012 Jun 12;2:83.

Macdonald MH. *Analysis and expression of Leishmania surface proteinase and glycoproteins* (Doctoral dissertation, University of British Columbia).

Mahmoodi M, Khamesipour A, Dowlati Y, Rafati S, Momeni AZ, Emamjomeh M, Hejazi H, Modabber F. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. Clinical & Experimental Immunology. 2003 Nov;134(2):303-8.

Maroli M, Feliciangeli MD, Bichaud L, Charrel RN, Gradoni L. Phlebotomine sandflies and the spreading of leishmaniases and other diseases of public health concern. Medical and veterinary entomology. 2013 Jun;27(2):123-47.

Mayrink W, Mendonça-Mendes A, de Paula JC, Siqueira LM, Marrocos SD, Dias ES, de Andrade HM, Machado-Coelho GL. Cluster randomised trial to evaluate the effectiveness of a vaccine against cutaneous leishmaniasis in the Caratinga microregion, south-east Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2013 Apr 1;107(4):212-9.

McMahon-Pratt D, Rodriguez D, Rodriguez JR, Zhang Y, Manson K, Bergman C, Rivas L, Rodriguez JF, Lohman KL, Ruddle NH. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infection and immunity. 1993 Aug;61(8):3351-9.

Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of Leishmania vaccines: predicting the future from past and present experience. Journal of biomedical research. 2012 Sep 30;27(2):85.

Müller MB. *Characterization of a New Large Family of Extinct Short Retroposons in the Protozoan Parasite Leishmania and Their Role in Post-transcriptional Regulation of Gene Expression* (Doctoral dissertation, Université Laval).

Nagill R, Kaur S. Vaccine candidates for leishmaniasis: a review. International immunopharmacology. 2011 Oct 1;11(10):1464-88.

Nehra[a] AK, Kumarib A, Moudgila AD, Vohraa S. Parasites in the. Organ-Specific Parasitic Diseases of Dogs and Cats. 2023 Mar 28:53.

Okwor I, Uzonna J. Social and economic burden of human leishmaniasis. The American journal of tropical medicine and hygiene. 2016 Mar 2;94(3):489.

Pakpour N. The role of central memory CD4+ T cells in Leishmania major infection. University of Pennsylvania; 2008.

Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL. Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS pathogens. 2009 Jun 19;5(6):e1000484.

Prieto JC. Studies on the Susceptibility of Leishmania mexicana mexicana to Drugs and Radiations. University of Glasgow (United Kingdom); 1984.

Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology. 2009 Dec;136(14):1915-34.

Rodriguez AE, Estévez JO, Nevot MC, Barrios A, Florin-Christensen M. Leishmania. Parasitic protozoa of farm animals and pets. 2018:289-311.

Rooholamini Z, Dianat-Moghadam H, Esmaeilifallah M, Khanahmad H. From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization. Frontiers in Public Health. 2024 Jul 5;12:1382996.

Rosado-Vallado M, Mut-Martin M, del Rosario García-Miss M, Dumonteil E. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine. 2005 Nov 16;23(46-47):5372-9.

Selvapandiyan A, Duncan R, Debrabant A, Lee N, Sreenivas G, Salotra P, Nakhasi HL. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian journal of medical research. 2006 Mar 1;123(3):455.

Soto M, Ramírez L, Solana JC, Cook EC, Hernández-García E, Requena JM, Iborra S. Inoculation of the Leishmania infantum hsp70-ii null mutant induces long-term protection against L. amazonensis infection in BALB/c mice. Microorganisms. 2021 Feb 12;9(2):363.

Tapia E, Pérez-Jiménez E, López-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12+ IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes and infection. 2003 Feb 1;5(2):73-84.

Thomaz-Soccol V, Ferreira da Costa ES, Karp SG, Junior Letti LA, Soccol FT, Soccol CR. Recent advances in vaccines against Leishmania based on patent applications. Recent patents on biotechnology. 2018 Mar 1;12(1):21-32.

Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Research. 2017 May 26;6:750.

Volpedo G, Huston RH, Holcomb EA, Pacheco-Fernandez T, Gannavaram S, Bhattacharya P, Nakhasi HL, Satoskar AR. From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection. Expert review of vaccines. 2021 Nov 2;20(11):1431-46.

Wamai RG, Kahn J, McGloin J, Ziaggi G. Visceral leishmaniasis: a global overview. Journal of Global Health Science. 2020 May 14;2(1).

Wilkins-Rodríguez AA, Escalona-Montaño AR, Aguirre-García M, Becker I, Gutiérrez-Kobeh L. Regulation of the expression of nitric oxide synthase by Leishmania mexicana amastigotes in murine dendritic cells. Experimental parasitology. 2010 Nov 1;126(3):426-34.

World Health Organization. WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization; 2022 Jun 8.

Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells

and protective immunity against leishmaniasis. Journal of immunology (Baltimore, Md.: 1950). 1990 Oct 1;145(7):2281-5.

Zamani P, Alavizadeh SH, Fakhraee F, Badiee A, Jalali SA, Chavoshian O, Khamesipour A, Kheiri MT, Mahboudi F, Jaafari MR. Multi-antigen vaccination with LPD nanoparticles containing rgp63 and rLmaC1N proteins induced effective immune response against leishmaniasis in animal model. Journal of Drug Delivery Science and Technology. 2021 Aug 1;64:102633.

Zutshi S, Kumar S, Chauhan P, Bansode Y, Nair A, Roy S, Sarkar A, Saha B. Anti-leishmanial vaccines: assumptions, approaches, and annulments. Vaccines. 2019 Oct 18;7(4):156.

979-8-89695-138-4